



MESOTHELIOMA UK

Annual Report

2024-25

Charity report and financials for Mesothelioma UK for period ending 31 March 2025.

Mesothelioma UK Registered Charity Number:
1177039

Registered Address:
235 Loughborough Road, Mountsorrel, Loughborough, Leicestershire, LE12 7AS

Contents

Foreword from the CEO	1
Objectives & Activities	2
How We Work	3
1. Improving Outcomes & Experiences	4
2. Research	16
3. Information	19
4. Awareness	21
5. Sustainability & Fundraising	23
Trustees Report	37
Looking Forward	40

Foreword from the CEO



Thank you and congratulations to the whole Mesothelioma UK team - our nurses, board of trustees, operational team, volunteers, ambassadors, our corporate and charity partners, and to everyone that has fundraised or donated to the charity. This is your charity and what you have achieved together, as you will see in this report, is exceptional.

Behind the scenes, the restructured operational team have been busy reorganising and team building. They are stronger than ever, with a more suitable structure and a clear vision that is outlined in the charity's new strategy that was published earlier this year.

The charity works closely with patients and their families to identify their needs and prioritises activities and services to meet them. The strength of our engagement has led to new courses for patients and carers and has influenced our research activities, with studies focused on peritoneal mesothelioma and the role of the coroner.

This last year, Mesothelioma UK has contributed significantly to awareness and prevention. People affected by mesothelioma often ask us to do all that we can to prevent others being exposed and put at risk. Through our research, reports, and communication, the charity has been able to give voice to people and share stories and experiences that have added invaluable clarity and truth to the UK's ongoing discussions and debate about asbestos.

To strengthen our awareness and prevention efforts, the charity has been partnering with companies across the UK involved in asbestos management. The benefits of collaboration are clear, as we work together to reduce the harmful impact of the UK's dreadful asbestos legacy.

The reputation of our nursing team grows year on year. They have been described as a 'tour de force'. Their contribution to the NHS, to mesothelioma treatment and care, and to the individual patients their support is appreciated and

acknowledged beyond the UK. This last year, the nursing team have responded to requests from South Africa, Japan, Cambodia, The Netherlands and Australia to network and share – attending educational events, and hosting visits and placements. Wherever our nurses go, and with whomever they connect, they carry with them our patients – their stories, their voices and their experiences. We are tremendously grateful to everyone who so generously and openly shares their story, allowing others to learn and find strength through their experiences.

It is tragic and shameful that the UK has such a dreadful asbestos legacy, but the Mesothelioma UK community is a shining example of our nation at its best; people pulling together and doing all that they can to help others and improve a seemingly impossible situation.

Thank you to each and every one of you that willingly works with and supports the community. The difference you make, detailed over the next few pages, is so appreciated.

Thank you.

Liz Darlison
CEO, Mesothelioma UK

Objectives & Activities

We are a national charity dedicated to supporting people affected by mesothelioma through expert care, information, and advocacy.

Our mission is twofold: to improve the lives of those living with the disease today and to help prevent future cases. We do this by championing equitable access to care, advancing research, and ensuring the voices of those with mesothelioma are heard.

Founded in 2004 as a Macmillan Cancer Support Resource Centre at University Hospitals of Leicester, Mesothelioma UK has grown from humble beginnings into a nationally recognised charity. We became

an independent organisation in 2008, and in 2018 registered as a Charitable Incorporated Organisation. By 2020, our charitable activity exceeded £1 million – a significant milestone in our development.

Since our inception, our core focus has been providing access to Mesothelioma Clinical Nurse Specialists (CNSs) where they are needed most – at the heart of the NHS and in hospitals across the UK. These specialist nurses offer invaluable support, delivering expert care, increasing access to clinical trials, expanding treatment options,

reducing emergency admissions, improving symptom management, and ultimately enhancing patients' quality of life.

We also recognise that many individuals diagnosed with mesothelioma are passionate about preventing future cases. That's why we collaborate with partner organisations to raise awareness about asbestos and highlight the devastating impact of mesothelioma nationwide.



How We Work

Five key pillars represent the scope and aims of the charity: Improving Outcomes & Experiences, Research, Information, Awareness, and Sustainability & Fundraising.

Our [strategy](#) gives more details on how we work. We use these pillars as a way to showcase our key activities and achievements throughout this report.

1. Improving Outcomes & Experiences

Our Nurse Team



Our mesothelioma nurses play a vital role in the care of people diagnosed with mesothelioma, providing expert holistic care and guidance through diagnosis, complex treatment pathways and symptom management.

This past year has continued to be challenging for all those working in the NHS, as healthcare teams continue to recover from the effects of the pandemic, meeting growing demand for services, and ongoing staff pressures. Despite all of this, our specialist mesothelioma nurses have continued to deliver outstanding care. Their dedication, compassion, and determination to support patients and families remain truly inspiring. They consistently go above and beyond to ensure people affected by mesothelioma receive the expert support they need.

As a charity, we know how tough the economic climate has been. This year we have focussed on sustainability and development of the team and every single one of our nurses continues to build their skills and knowledge, helping to make sure we deliver the highest standards of mesothelioma care across the UK.

Our nurses have continued to showcase their work and educate others at a variety of esteemed conferences - including the British Thoracic Oncology Group and Lung Cancer Nursing UK. They have also worked alongside Lung Cancer Nursing UK to develop an online educational resource for lung cancer nurses. The nurses have continued to lead and support local events, raise

awareness, and play a key role in fundraising and support group activities across the country – especially on Action Mesothelioma Day.

We remain focused on reaching people affected by mesothelioma in all parts of the UK. In Scotland, our nurses are at the heart of the Scottish Mesothelioma Network, helping to provide coordinated care through a national clinical team. In Wales, we have been working to ensure people diagnosed with mesothelioma and their families continue to have access to a dedicated mesothelioma nurse. We have continued to develop strong partnerships with clinical teams in Northern Ireland and Macmillan which led to the country's first mesothelioma nurse posts being established in September.

We launched our new Mesothelioma UK Nursing Network with the aim of sharing knowledge, supporting one another, and driving improvements in care. In January we shared the first edition of *Mesothelioma in Focus*, our newsletter written specifically for healthcare professionals to keep them up to date on the latest developments in mesothelioma treatment and care.

As we look to the year ahead our nurses are preparing to present their work at the biannual International Mesothelioma Interest Group Conference (iMig) which will be held in Philadelphia, USA in October 2025. The Mesothelioma UK nurse specialist model is internationally recognised as best practice in mesothelioma nursing.

Finally, I want to say a huge thank you to our nurses – for their energy, compassion, and unwavering commitment to the mesothelioma community. I am proud to support them and look forward to what the next year will bring.

Leah Taylor
Head of Nursing

Nursing Team Update

Welcoming new faces and fond farewells

Over the past year, we welcomed new nurses to our team and said heartfelt goodbyes to several valued colleagues who have made a lasting impact on our work.

We bid farewell to:



Anne Moylan, one of our longest-serving senior nurses, spent ten dedicated years with the charity. Based in Portsmouth, Anne served as a Team Leader and led much of our work with the Armed Forces community. She has now taken on a new challenge, bringing her skills and experience to a lung screening programme.




Becky Weston-Thomas, based at Aneurin Bevan University Health Board in Wales, joined us after a gap in service following the retirement of our previous Project Lead. Becky ensured that patients continued to receive specialist mesothelioma nursing support. She left the team in November to take up a new role in cancer care.



Sophie Phillips, our mesothelioma nurse in Birmingham, retired in September after a distinguished and impactful career. Sophie was a key source of support for patients across the West Midlands and is deeply missed by colleagues and the community alike.



Sam Jayasekara, based at Broomfield Hospital, provided essential support across Essex. A highly experienced nurse specialist, Sam was involved in several key charity projects, including the delivery of our Carers Course. She relocated in December and continues her work within cancer care.



Catherine Stoten joined the nursing team in March 2023 as the first mesothelioma nurse at University College London Hospital. Before moving overseas, Cat played a crucial role in establishing the mesothelioma nursing service there, leaving a solid foundation for her successor.

We thank Anne, Sophie, Catherine, Becky, and Sam for their dedication and compassion. Their contributions have made a significant difference to the lives of those affected by mesothelioma, and we wish them all the very best in their future endeavours.

At the same time, we were pleased to welcome five new nurses to the team, each bringing a wealth of experience and expertise:



Karen Connolly

joined in August, working within the lung cancer team at St Bartholomew's Hospital in London.



Stephanie Todd and Carol Johnston

were welcomed to the team in September. Stephanie and Carol are based within Belfast Health and Social Care Trust and have joined us as the first mesothelioma nurses in Northern Ireland. Their posts are generously funded by Macmillan Cancer Support for the first three years.



Sonya Moudart

became part of the lung cancer team at University College Hospital London in December.



Lyndsey Haffenden

joined us in January and is based at Cwm Taf University Health Board in Wales. Lyndsey's post is generously funded by Macmillan Cancer Support for the first two years.

We are incredibly grateful to our partners, many of whom have generously funded key nursing posts and continue to be a vital source of support for our entire team. Their commitment, along with the efforts of their donors and fundraisers, makes it possible for us to make a meaningful and lasting impact on the lives of people affected by mesothelioma across the UK.

Facts & Figures

Total number of new patients

referred to one of our Mesothelioma UK nurses

1,031

Similar numbers reported in last fiscal year

Episodes of care* provided

by our Mesothelioma UK nurses for both new and existing mesothelioma patients

36,961

* Support and advice on topics including symptoms, pain, treatment options, clinical trials, psychological support

24% more than in previous fiscal year

Total number of support groups attended*

368

* Groups held locally or virtually where patients and families can meet our nurses, ask questions, and feel supported

Similar numbers reported in last fiscal year

Number of MDT* meetings attended

929

* Multi-Disciplinary Team – group of healthcare professionals working together to make decisions on the best course of care for patients

Similar numbers reported in last fiscal year

Nurse Case Study

Recognised for her expertise nationally and internationally, Sam regularly shares her knowledge on prominent platforms.



Samantha Westbrook

The first Peritoneal Mesothelioma Clinical Nurse Specialist in the UK

Since her appointment in 2018, Samantha Westbrook has been a pioneering force in the care of people affected by peritoneal mesothelioma – the UK's first nurse specialist dedicated exclusively to this role.

Based at the Peritoneal Malignancy Institute within Basingstoke and North Hampshire NHS Trust, Sam plays a vital role in a large, multidisciplinary team focused on peritoneal disease.

Sam independently manages a national caseload of adults living with peritoneal mesothelioma, working closely with local and regional healthcare teams across the UK to ensure patients receive timely and specialist care. She is a core member of the peritoneal mesothelioma multidisciplinary team (MDT), which meets twice monthly to develop personalised treatment plans that are communicated to local hospital teams.

Beyond clinical duties, Sam is a cornerstone of patient support. She hosts the Mesothelioma UK Facebook group – a closed community for people affected by peritoneal mesothelioma – and facilitates two virtual support groups monthly, a dedicated WhatsApp group, and a unique buddy system. These services connect patients both nationally and internationally, fostering a supportive network. Additionally, Sam co-organises an annual wellbeing event with the Peritoneal Malignancy Institute and HASAG, offering patients the opportunity to learn from specialists and each other.

Sam is active in research, co-leading a study in partnership with the Mesothelioma UK Research Centre at the University of Sheffield, examining patient pathways and care experiences.

Recognised for her expertise nationally and internationally, Sam regularly shares her knowledge on prominent platforms to advance peritoneal mesothelioma treatment and care.

Sam's role is funded by Mesothelioma UK.

Highlight on Wales

Project Cymru ran for three years until 2023, with the goal of developing a cohesive mesothelioma service across Wales.

Central to this vision was the creation of a hub-and-spoke model, anchored by an all-Wales specialist mesothelioma multidisciplinary team (MDT). While funding for the MDT was approved by the Welsh Health Specialised Services Committee (WHSSC), progress toward establishing the service has been limited.

Following the retirement of our project lead, the charity's focus shifted to reinstating and sustaining a mesothelioma clinical nurse specialist (CNS) post in Wales, with initial support from Macmillan Cancer Support. A new CNS post was established at the end of 2023; however, the postholder departed after a year, resulting in another gap in provision. In January 2025, a new nursing post was appointed at Cwm Taf University Health Board, and discussions are ongoing regarding a further position at Aneurin Bevan University Health Board to help maintain access to specialist mesothelioma nursing support.

We are sincerely grateful to Macmillan Cancer Support for their funding and commitment, which remains essential to sustaining mesothelioma nursing services across Wales.



Quality Performance Indicators (QPIs) measuring outcomes that reflect the quality of care and processes delivered across the network is gathered by the MDT coordinator and audit facilitator. This allows continuous improvements in services and outcomes, including patient survival and quality of life. The initial baseline review of the network's QPIs took place in 2021 with a further review reflecting three years of data [now available](#).

Information and Support

Website:

The SMN has a dedicated website with information for patients in Scotland on how to access treatment, clinical trials, support groups and other relevant information. This can be accessed by clicking this link: [Scottish Mesothelioma Network](#).

Patient Information:

The network has continued to provide nationally agreed, standardised patient information packs across every health board region to anyone diagnosed with mesothelioma. This pack contains a mesothelioma patient information booklet, local asbestos charity information and contact details, Mesothelioma UK care record, Mesothelioma UK keeping-in-touch card and clinical trials app details, an invitation to the network support group and local Mesothelioma CNS contact details.

Newsletter:

A regular network newsletter has been created to help raise awareness and share all the news and developments in relation to mesothelioma across Scotland and the SMN itself. It is sent to all members of the network and our partner organisations. It is also sent to all the Scottish Lung Cancer CNSs (via the Scottish Lung Cancer CNS Forum) and is available to patients and their families if desired via the network website. The current issue along with a back catalogue can be viewed on the Scottish Mesothelioma Network website.

Education Events:

The network team continue to host an annual education and networking event for health care professionals and those with a specialist interest in the care of those affected by a diagnosis of mesothelioma.

Highlights from 2024/2025

- Sustained delivery of high quality clinical care across the country.
- Improved access to diagnostic procedures, with local anaesthetic thoracoscopy now available in each of the health board region.
- Multicentre ambispective cohort study evidencing the impact of the network since its launch, suggests improved survival of patients with pleural mesothelioma and evidences the benefit of the expert National MDT Model.
- Clinical Audit of Mesothelioma Quality Performance Indicators (QPIs) comparison demonstrated improvements in the diagnostic pathway (imaging and histopathology) over the past four years of QPI reporting.
- National Clinical Management Guidelines for mesothelioma have been developed in collaboration with clinical representatives from all specialities and regions across Scotland.
- Successful implementation of key performance indicators for the network's MDT coordinator and audit facilitator roles, evidencing the value of the role in coordinating the patient pathway nationally.
- Successful in person education event at the Royal College of Physicians in Edinburgh on 6 February was attended by 80 representatives from the mesothelioma community clinical and support services from across the country.

The year ahead

Over the coming year, the network is looking forward to:

- Formal publication of the SMN MDT Impact Evaluation.
- The final review, consultation and publication of national clinical management guidelines.
- Launch of our new online Support Group, facilitated by Mesothelioma UK.
- Development of a Patient Reported Outcome Measures Working Group.
- Ongoing QPI reporting and production of an Annual Clinical Audit Report.
- Ongoing weekly national MDT meetings.
- Ongoing high quality equitable care, information, support, and access to clinical trials for all patients affected by Mesothelioma across Scotland.

Project Northern Ireland

Reflection on the new regional mesothelioma clinical nurse specialist service

Mesothelioma is a rare and aggressive cancer primarily caused by asbestos exposure. In Northern Ireland, the incidence of mesothelioma reflects the region's industrial history, particularly its shipbuilding sector.

Approximately 50 people are diagnosed with mesothelioma each year in Northern Ireland. Most cases occur in individuals aged 60-80, with men being more commonly affected than women.

Northern Ireland has been the only region within the United Kingdom without a designated mesothelioma clinical nurse specialist resulting in patients with mesothelioma not having access to the same specialist knowledge, skills and expertise as those in other parts of the UK.

Due to this there has been an aspiration by Mesothelioma UK to align Northern Ireland with England, Scotland and Wales in relation to the provision of a mesothelioma nursing service. This was the vision several years ago of the CEO of Mesothelioma UK, Liz Darlison. However, this service really came to fruition due to the drive and determination of The Rodgers family from Northern Ireland who initially engaged with Mesothelioma UK when a family member was diagnosed.

The family have since worked tirelessly raising funds and awareness alongside Mesothelioma UK for the last few years to establish this specialist nursing role in Northern Ireland.

Fortunately, the vision was also shared by Macmillan who have generously funded the role for the first three years with onward funding by Mesothelioma UK and Belfast Trust. Broken down this is 0.4 whole time equivalent (WTE) funded by Mesothelioma UK and 0.6 WTE via the Belfast Health and Social Care Trust, through agreed commissioned Clinical Nurse Specialist funding.



The post of the regional mesothelioma CNS service commenced 1 September 2024. It is a Band 7 role of 37.5hrs/week with post holders covering 18.75hrs/week each. Both post holders are working their remaining hours as Lung Cancer Clinical Nurse Specialists.

The post is based within the Belfast Health & Social Care Trust (BHSCT) but provides a service for patients with mesothelioma in the Northern, Southern, South Eastern and Western Trusts.

The BHSCT has four hospital sites with three of these sites being the main location where patients with mesothelioma will be admitted or attending as outpatients. The mesothelioma CNS acts as keyworker for these patients within BHSCT and is a conduit for health professionals and patient/relatives with information pertaining to mesothelioma offering advice, support and education province wide.

The initial phase has centred on establishing the service, with a key focus on analysing current mesothelioma diagnosis statistics and patient demographics. This scoping exercise has provided valuable insight into population needs and laid the foundation for shaping the direction and future development of the service.

To date, patients and their families have expressed gratitude for the support provided and the ability to access the Mesothelioma CNS service when queries arise. While no formal patient satisfaction questionnaire has yet been implemented, plans are in place to introduce feedback mechanisms as the service continues to grow and become more established. A Care Opinion QR code has been included on the patient information leaflet to encourage informal feedback.

Real Stories



Living Life Fully: Caroline Lyons' Legacy

Caroline's nursing jobs had taken her from army hospitals in Northern Ireland, Germany and Hong Kong, all over the NHS and in international primary healthcare schools in rural communities.

After pursuing their careers, husband and wife, Darren and Caroline Lyons moved to their dream destination of Cornwall. They renovated an old house and planned to retire there.

However, after a period of illness in 2020, Caroline was sadly diagnosed with mesothelioma. Although Caroline tragically passed away from the disease in October after a 20 month battle, her legacy now lives on through Darren and daughter, Anna.

A time of real highs and lows

Darren says: "Following an accident where Caroline broke her leg, she then developed a pain in her shoulder

blade, which physio didn't help. By Christmas 2020, she contracted the flu or a chest infection which prescribed antibiotics didn't clear. Following an X-ray and a CT scan, she was diagnosed with mesothelioma. It was a massive shock and on Christmas Eve, our daughter announced her pregnancy, so it was a time of real highs and lows."

Support from nursing teams

Darren continues: "The treatment and care that Caroline received was brilliant. She was referred to the mesothelioma team in Truro and we also made connection with the palliative care team."

"In July, we visited Anna, Anthony and baby Poppy who live in Glasgow, but Caroline's health worsened and we could not return to Cornwall. Desperate to survive to see Poppy's first birthday, Caroline was reluctant to engage with symptom management and end-of-life planning. But only days after Poppy's birthday in September 2022, Caroline deteriorated, eventually being admitted into the local hospice and passed away just 30 hours later."

Progressing with civil claim

"We were encouraged to pursue a civil claim and engaged Hugh James solicitors who went through Caroline's work history. She'd had low level exposure in hospitals and worked in couple of hospitals that had been built with asbestos during wartime but were demolished in the 1990s," says Darren.

"After a 3-4 year investigation, Hugh James are now putting court papers in so although it can be a long process, Caroline wanted to highlight the dangers of asbestos exposure and bring it to the attention of employers. Irrespective of its success, making a claim does hold those responsible for our welfare to account."

Changes all round

Darren reflects: "In tribute to Caroline, Anna and I are determined to live our best lives, without fear, doubt or compromise. I think Caroline would agree!"

Benefits

Advisors

Access to timely, expert benefits and compensation advice continues to be essential for people diagnosed with mesothelioma. At Mesothelioma UK, we remain committed to ensuring that patients and their families receive the support they need, regardless of location or financial background.

We have built on our existing provision in North East England, led by our Benefits Manager Sarah Thomas, and expanded our reach significantly this year following the successful application for funding from B&CE. This has allowed us to recruit two new Benefits Advisors, Angela Kingston-Nash and Claire Reeves, who are now actively supporting patients in the Bristol and Avon area, as well as responding to national and international enquiries through the Mesothelioma UK Support Line.

To ensure continuity and quality of service, the new advisors underwent an in-depth induction which included training on the complex entitlements available to mesothelioma patients and internal case management systems. They are now fully integrated into our operations team and building relationships with the asbestos community in the Bristol and Avon area.

Their recruitment has strengthened our national coverage and significantly increased our capacity to provide personalised, specialist advice to patients and their families.

We continue to collaborate closely with members of the Asbestos Victims Support Group Forum across the UK, ensuring that patients who contact us can be referred to trusted local specialists where appropriate. We also maintain strong links with healthcare professionals and regularly contribute to training and educational events within the mesothelioma clinical community to raise awareness of the financial support available.

DWP processing delays and campaigning

One of the major challenges remains the delays in processing Industrial Injuries Disablement Benefit and government lump sum payments.

Despite ongoing advocacy and media efforts by Mesothelioma UK, many patients continue to face distressing delays, with some not surviving long enough to receive their entitlements.

In response to growing concern, we met with Sir Stephen Timms MP, Minister of State for Social Security and Disability within the Department for Work and Pensions (DWP) to raise these issues directly. We were reassured that steps are being taken within the DWP to improve processing times. Early statistics suggest a modest improvement, but the pace of change remains slow. We will continue to campaign robustly for urgent reform to ensure patients are not left waiting in their time of greatest need.

Facts & Figures 2024-25

Total number of clients

105

Lump sum payments identified

£1,475,749

Estimated annualised benefits

£1,154,538


Vets UK lump sum

£420,000

Support Line

The Mesothelioma UK Support Line sits at the centre of the support services provided by the charity. A freephone number (Mon-Thurs 9am-4pm, Fri 9am-3pm) provides access to expert support and advice for those not able to find this locally.


In 2023/2024 the Mesothelioma UK Support Line dealt with 359 contacts for support across the three media currently available.



CONTACTS

The medium by which people choose to contact us remains constant with two out of every three people choosing to pick up the phone and speak to us

- Via telephone
- Via email
- Via website




WHO CONTACTS US FOR SUPPORT AND ADVICE?

There has been a slight year on year increase in the percentage of those contacting us being patients themselves. The bigger percentage remains constant year on year, with contacts from relatives and carers making up two thirds of our overall contact numbers.

- Patients
- Relatives/Carers
- Other (eg. healthcare professional, well but worried, patient travel)

Calls from those who are well but worried about exposure, averages out at 9% of our calls over the fiscal year 2024/25 but it is worth noting that the second half of the year saw these types of calls increase significantly. We believe this to be a direct consequence of increased media coverage in newspapers and on TV about the dangers asbestos still poses in the UK.

Support Line



Most contacts are about compensation and benefits, symptom and pain management, and new diagnosis and treatment options. This shows a continuing need for our support services for those who are not receiving this information and advice locally.

The Support Line Quality Group continue to meet regularly to monitor these contacts for timeliness and quality of response as well as identifying any gaps in knowledge and training needs within our team. This ensures that our Support Line Service is the best it can be for our patients, their loved ones, our Nursing Team and Mesothelioma UK as a charity.




2. Research

Introduction

Mesothelioma UK aims to support high quality mesothelioma research in the UK, focusing on prevention, new treatments and quality of life. Our goal is to fund pioneering research, promote equitable access to clinical trials and advocate for a National Mesothelioma Audit.

We continue to be proud members of the Association of Medical Research Charities, whose support and guidance we deeply appreciate. We remain steadfast in our commitment to our research objectives. We are immensely grateful to our Research Advisory Steering Committee for their commitment, ensuring that when funding becomes available, we will continue to support only the highest quality research.



National Mesothelioma audit

Mesothelioma UK remains firmly committed to reinstating the National Mesothelioma Audit – a vital project that, due to funding constraints, has not been undertaken since 2018. This audit, published in 2020 highlighted that, while improvements had been made in some areas such as survival, pathologic sub typing and clinical nurse specialist assessment, variation in active treatments and outcomes existed at cancer alliance and organisational level across the UK. A national audit of this scale provides essential insights into diagnosis, treatment, and patient care, helping us understand who is affected by mesothelioma and how services can be improved.

The findings are crucial in driving equity of access, improving treatment pathways, and informing evidence-based care across the UK. We will be exploring all available options with key stakeholders and partners to ensure that, once reinstated, the audit can be sustainably embedded for the future.

Our aim is to establish a long-term model that prevents future gaps in this vital national data. Re-establishing the National Mesothelioma Audit will be a key priority in our new 2025-2028 strategy, reflecting our ongoing commitment to improving outcomes and quality of life for everyone affected by mesothelioma across the UK.

Active Grants



University
of Glasgow

Leveraging clonal genomics to augment diagnostic accuracy and forecast survival in mesothelioma

The aim of this study is to examine the feasibility of a randomised trial of exercise therapy in mesothelioma. The EXTRA-Meso study represents an opportunity to address the unmet need for patients with mesothelioma to improve their wellbeing, physical and functional fitness and health-related quality of life.

Completed Grant 2024-25



UNIVERSITY OF
BIRMINGHAM

Leveraging a new class of cancer target for the benefit of mesothelioma diagnosis and treatment

This was a small, initial grant for six months. Research has shown that MDIG (Mineral Dust Induced Gene),

a gene that has been identified as playing a role in the development and progression of certain cancers, could be a useful target for new mesothelioma treatments. In the short term, this means we should do more studies on how MDIG works in mesothelioma cells and develop drugs to block it. In the long term, it supports further studies to test these drugs and combination therapies, which could lead to better treatments for patients. This grant has helped confirm the initial idea and gather data to apply for larger grants in the future.



Update from the Mesothelioma UK Research Centre



The Mesothelioma UK Research Centre at the University of Sheffield was established in 2020 and is funded by Mesothelioma UK in addition to other national charities and funding organisations.

The end of June 2025 marked an incredible five years for the Research Centre. The team have conducted a programme of research to benefit the care of people diagnosed with mesothelioma and their families and since 2020 have successfully completed over 20 research studies. In 2024/5 the Research Centre completed studies on the role of the coroner/procurator fiscal in mesothelioma and the support needs of family carers in mesothelioma. A nested study within the HIT-MESO clinical trial is also ongoing, which will explore patient experiences of receiving proton beam radiotherapy treatment. In Oct 2024, the team were delighted to welcome a new PhD student (Caitlin Lusted), who will be conducting research into 'scanxiety' and the experiences of undergoing scans for mesothelioma. These studies complement our existing portfolio of projects, which all respond to top priorities for mesothelioma research, as identified in our 2021 Research Prioritisation Exercise.

Since the Research Centre was established, the team have achieved the following:

- Published over 200 research outputs.
- Published 31 papers in peer review journals (eg. Journal of Advanced Nursing, Palliative Medicine, European Journal of Oncology Nursing).
- 91 posters and oral presentations presented at conferences including iMIG, BTOG, ITONF, LCNUK, IASLC.
- 47 invited presentations contributed at professional events eg. law firms, ASG's, asbestos monitoring industry seminars.
- Submitted 25 policy/parliamentary contributions.
- Contributed to 104 public engagement events including creating animations and films, infographics and events at the Festival of the Mind and Festival of Social Sciences.
- Developed and premiered the play 'Invisible Threads' highlighting issues around asbestos and mesothelioma.
- Website has had over 20,000 views since it was launched.
- In September 2025, our book 'Living with Mesothelioma' will be published by Routledge.

Our website has had over 20,000 views since it was launched and provides details of all research outputs and studies. We have a dedicated 'Resources' webpage which is a repository of professional resources, and a 'Patient and Public Involvement (PPI)' webpage which provides details of PPI opportunities.

The Research Centre has also been working hard to support other early career mesothelioma researchers and have provided mentoring and advice to students, nurses, doctors and other aspiring academics.

The Research Centre is led by Prof Angela Tod and Prof Clare Gardiner who work with a team of researchers and PhD students, supported by a Patient and Public Involvement (PPI) panel.

More information about the Mesothelioma UK Research Centre can be found on their website: www.sheffield.ac.uk/murc.

3. Information

At Mesothelioma UK, we are committed to empowering patients and families with timely, accurate, and accessible information.

Our leaflets and booklets are designed to support everyone affected by mesothelioma – whether newly diagnosed, undergoing treatment, or seeking practical guidance. These resources are available to download and are written in clear, compassionate language to help individuals make informed decisions about their care.



We are proud to hold the PIF TICK accreditation, the UK's trusted quality mark for health information, awarded by the Patient Information Forum. This recognition reflects our dedication to








producing evidence-based, user-tested materials that meet rigorous standards of clarity, relevance, and accessibility.

Our information covers a wide range of topics – from understanding mesothelioma and treatment options to managing symptoms and accessing support services. By continually reviewing and updating our materials,

we ensure they remain responsive to the evolving needs of the mesothelioma community.

Number
of leaflets
distributed

9,086




Our Communications


Mesothelioma Matters:

Keeping the mesothelioma community informed and connected

Our bi-monthly e-bulletin, Mesothelioma Matters, reaches patients, carers, and supporters with updates that matter most. Each edition features real-life stories, news from the charity, updates on mesothelioma research and clinical trials and more. With 1,780 subscribers, Mesothelioma Matters plays a key role in keeping our community informed, engaged, and supported.



Social media



We use our social media channels – Facebook, Instagram, X (formerly Twitter), and LinkedIn – to share timely updates on advocacy, research, clinical trials, and charity news. We also spotlight personal stories from across the mesothelioma community, helping raise awareness and build connection.



www.facebook.com/therealmesouk



[@mesotheliomauk](https://www.instagram.com/mesotheliomauk)



<https://uk.linkedin.com/company/mesothelioma-uk>



<https://x.com/Mesouk>



[Patient stories](#)

Mesothelioma UK website

Our website remains a vital resource for anyone affected by mesothelioma. It offers clinically led accessible information on diagnosis, treatment and support services, and patient resources.

In the past year, we've seen:


New users

24,232

Total page views

125,063

We are committed to maintaining a trusted online hub for everyone who needs us – from newly diagnosed patients to healthcare professionals and loved ones.



4. Awareness

Awareness is the fourth pillar of Mesothelioma UK's strategy. Supporters and donors often tell us they want to see everything possible done to prevent future generations from facing mesothelioma.

This pillar responds directly to that call – gathering lived experience, empowering patients and families to share their stories, and using our platform to reach the widest possible audience. Our ultimate aim is twofold: to stop mesothelioma before it starts, and to drive lasting improvements in care and treatment for those already affected.

How we do this:

1. Amplifying the patient voice

We work closely with patients to help them share their experiences – turning personal stories into powerful advocacy. This year, we partnered with companies managing asbestos who, alongside becoming regular donors, helped us produce moving video footage of patients telling their story. These films are now central to our education and training programmes, ensuring the voices of those living with the UK's asbestos tragedy are heard where they matter most.



2. Raising the profile of mesothelioma

Building a stronger media presence is vital to raising awareness of mesothelioma and the urgent need for action. Over the past year, Mesothelioma UK has engaged traditional media outlets, developed social media content, and created materials that bring the human stories behind the UK's asbestos tragedy to wider audiences.



Our Action Mesothelioma Day campaign in June/July 2024 was a standout success, driving some of the highest engagement we've seen all year. Posts on Instagram and LinkedIn proved especially popular, collectively reaching almost 4,000 impressions and helping to raise vital awareness of mesothelioma.


This work was bolstered by a restructure of the leadership team and the appointment of a Digital Marketing & Content Coordinator in March 2025. While this came at the end of the financial year, we could already see the enhancements in the quality and consistency of our online content and the strengthening of our presence across platforms, particularly on LinkedIn.

We also provided direct support to journalists covering mesothelioma-related issues, connecting them with patients and families to bring depth and authenticity to their reporting. In addition, we advised on a storyline in a prime-time television programme and helped secure patient voices on breakfast television, reaching national audiences and raising the profile of the disease.

3. Championing Better Treatments, Care and Services

Raising awareness is not only about public understanding – it also means ensuring that health professionals and policymakers recognise the unique needs of people with mesothelioma. Through our partnership with the Mesothelioma UK Research Centre at the University of Sheffield, we generate evidence that shines a light on these needs, from the psychological effects of mesothelioma on veterans to the challenges faced by long-term survivors and carers.

In addition, research inspired by our nursing team and the patients they support was undertaken by the Mesothelioma UK Research Centre, revealing the prevalence of mesothelioma linked to asbestos exposure in educational settings across the UK. These insights strengthen our campaigns and provide evidence to influence policymakers, regulators, and the wider public.



By sharing these findings widely, we can influence practice, improve services, and ensure that the voices of patients and families are heard at every level of decision-making.

4. Campaigning for Safer Environments

In October 2024, Mesothelioma UK supported the launch of a campaign in the Daily Mail aimed at removing asbestos from schools and hospitals. This initiative was prompted by a report predicting that tens of thousands of students and teachers would die from mesothelioma due to exposure to asbestos in these institutions.

The campaign highlighted the urgent need for comprehensive action to address the ongoing risks of asbestos exposure in public buildings. Mesothelioma UK's Chief Executive, Liz Darlison was interviewed by the Daily Mail for the campaign. We also helped to liaise with nurses, patients, unions and stakeholders to gather information for the journalists working on the campaign.

Looking ahead

The Mesothelioma UK operational team has established an External Affairs Work Group to coordinate our messaging and ensure our priorities are communicated clearly and effectively. At the heart of our work, we take our lead from the patients and families we support, sharing their experiences to raise awareness of mesothelioma and the ongoing risks of asbestos exposure. In the coming year, we will focus on:

- **Amplifying patient and family voices** through media, storytelling, and digital channels.
- **Highlighting key campaigns and initiatives** that promote safer environments and improved care.
- **Funding and promoting research studies** that enhance understanding of mesothelioma and inform improvements in treatment and support.
- **Engaging with MPs, government, and policymakers** to influence change at the highest level and keep mesothelioma firmly on the national agenda.
- **Working with healthcare professionals and the wider public** to strengthen understanding of mesothelioma and its impact.

Through these efforts, Mesothelioma UK aims to ensure that awareness translates into action – from earlier diagnosis and better care to prevention of future asbestos-related tragedies.

5. Sustainability & Fundraising



A year of community, commitment and impact

Over the past year, the mesothelioma community has come together in powerful and inspiring ways to support our mission.

From incredible fundraising feats to steadfast volunteering and partnership work, the dedication shown by individuals and organisations across the UK has been truly extraordinary.

We are continually humbled by the passion and creativity of our supporters – whether climbing mountains, hosting bake sales, sharing stories, or simply giving what they can. Every action helps raise vital awareness and funds, and every gesture brings us closer to better outcomes for those affected by mesothelioma.

As we look ahead, we remain focused on delivering the objectives set out in our strategy. To sustain and grow our impact, we are committed to:

- Building sustainable income to secure the future of our services
- Strengthening governance and support structures to enable responsible growth
- Developing and supporting a high-performing team dedicated to making a tangible difference

Our sincere thanks go to every donor, volunteer, fundraiser, trust, foundation, corporate partner, and member of our Legal Panel. Your continued belief in our work means the world to us.

Thank you for standing with us. Together, we are making mesothelioma matter.

Glitz, Generosity, and Groundbreaking Fundraising

In October, David and Ali Staley hosted the 'Meso Live Better, Live Longer' Ball at Edgeley Park in Stockport, an unforgettable evening filled with glitz, glamour and incredible generosity.

The event raised awareness about the dangers of asbestos and vital funds for Mesothelioma UK, bringing together friends, family and supporters. Liz Darlison, Mesothelioma UK CEO said: "It was just overwhelming how much love was in that room for David, Ali and their children, Josh and Erin. The support they have from so many is just heartwarming and the event - well, all I can say is wow! We are truly grateful to all those who have supported and helped Dave and Ali achieve so much. This is the biggest single event fundraiser ever for Mesothelioma UK! Thank you."

Reflecting on the ball, David said: "The night could not have gone any better – we raised awareness about the dangers of asbestos, we raised the profile and vital funds for Mesothelioma UK, we invited our specialist mesothelioma medical team to join us, and the whole evening was amazing. The only complaint was having to stop dancing and vacate at midnight – as from all accounts, no one wanted to leave!!!!

"Just a huge, massive thank you to everyone who contributed, whether you were there on the night or from your kind messages of support, to generous donations via JustGiving too. The support and generosity from everyone is beyond belief and we are absolutely delighted to announce that we raised a massive £39,055.59! This will make a significant difference and for example, will fund a Mesothelioma UK specialist nurse for more than a year!"



24
Active volunteers

Fundraising
pages opened

327

Community Fundraising

Year after year we are always so impressed and inspired by our wonderful fundraisers, this year is no different! Check out some of the ways our fundraisers have made an impact this year.

Challenges



London Landmarks

In April 2024, we had another brilliant turnout of keen runners ready to take on the challenge of the London Landmarks Half Marathon. Despite the surprisingly cold winds, 19 people turned up to complete the race in support of Mesothelioma UK. It was a wonderful day with a fantastic atmosphere and our Community Fundraising Team were there to cheer them on past the finish line.

Fundraising is no easy task and we are so grateful for the support and dedication from our incredible fundraisers in raising vital funds and awareness for Mesothelioma UK. Together, they raised an amazing **£17,564.79** (including Gift Aid).

“Having run marathons in the past, I’m a bit of a seasoned runner and really wanted to take part in the London Landmarks Half Marathon as I have some friends that were running. I was scrolling through the list of charities and Mesothelioma UK jumped out straight away. My dad passed away from mesothelioma back in 2004, so this charity was perfect for me to fundraise for. It was one of the best feelings I’ve had running, after having a year full of injuries, and being able to cross that finish line with my dad in my thoughts. I had an amazing weekend and to raise money for a charity that means a lot made it even better.”

Dan Stanley – ran LLHM2024



Great North Run

Another wet and windy day for the Great North Run 2024 saw 29 runners lace up their shoes and push through some challenging weather conditions to support our mission and complete the 13.1 miles from Newcastle to South Shields. Whether running in memory of a loved one, raising awareness for a cause close to their hearts, or simply aiming to make a difference, they all showed great determination to complete the race in support of Mesothelioma UK. A huge thank you to everyone involved, including Lucion, a technology-led environmental services consultancy who had 10 of their employees taking part. Together, our runners raised an incredible **£24,194.16** (including Gift Aid).

Our community fundraisers raised **£325,565.99**

Fundraising Stories



Muffins for Meso

Our Muffins for Meso campaign ran throughout the month of May with over 50 bake sales being held with work colleagues, families, friends and support groups. From homemade cakes and biscuits to beautifully decorated cupcakes, each treat played a part in raising vital funds and awareness. We are so incredibly grateful to everyone for coming together and raising an amazing **£5,415.63**. These small acts of kindness make such a big difference.



Fitness Feb

Fitness February was another great success to kickstart 2025. We had supporters from all walks of life taking part and turning their workouts into a powerful way to give back. Whether walking, running, cycling, or joining fitness classes, each participant pushed themselves to raise funds and awareness in support of Mesothelioma UK. Every step, rep and mile contributed to making a difference to all those affected by mesothelioma. We are so thankful to everyone that took part and helped raise a fantastic **£4,597**.

Our Volunteers

At Mesothelioma UK, we are incredibly grateful to our wonderful group of volunteers who give their time and dedication to supporting us in so many ways throughout the community. Their commitment brings hope, support and positive change to so many lives. Whether supporting us virtually through proofreading and sharing on social media, or in person by helping at our events – it all makes such a meaningful and lasting impact.



Sian Thomas started volunteering for Mesothelioma UK after losing her mum, Annette, to mesothelioma in 2018.

“I’m Australian and my mum and our family were helped by Gippsland Asbestos Related Disease Support (GARDS). When I returned to the UK, I wanted to give back some of the help and support that my family had been given. Losing someone you love can leave you feeling powerless, but volunteering helps me feel that I’m playing a small, positive part.

I volunteer as a proofreader. This means I check documents like patient information leaflets to make sure they are in plain English and grammatically correct. It feels really rewarding using my skills to support the hard work of the Mesothelioma UK team. I remember how important it was to have access to clear, reliable information after mum’s diagnosis when we felt anxious and overwhelmed. I hope that when patients and their families read the leaflets I contribute to, they can easily understand the information inside and feel it has been written with them in mind.

I can do the proofreading at home, at times that are convenient for me, but I have also had the opportunity to meet other Mesothelioma UK volunteers and staff. Even though I volunteer remotely, I do feel part of a team all working together to help people living with mesothelioma.”



In November 2024, Liam Bradley, Mike Goodchild and Rob Juby set off on a 140-mile route to raise awareness of mesothelioma and vital funds for Mesothelioma UK.

Accompanied by friends and colleagues at various points along the way, they set off from Portman Road, home of Ipswich Town Football Club to Nottingham Forest’s City Ground arriving five days later in time for the Premier League game between the two sides. Mesothelioma UK assembled an enthusiastic team of volunteers to cheer, clap and spur them along over the finish line.

Thank you to all of our volunteers for their support.

Our Ambassadors


Charity ambassadors play a vital role in supporting our work and championing our mission. They help to connect the charity with the wider community, acting as a bridge that builds strong networks of professional contacts and potential partners.

Our ambassadors bring a wealth of experience from a variety of fields. Some have been personally affected by mesothelioma, while others work within the sector. With their individual expertise and passion, they not only support the charity's goals but also actively engage with and encourage our dedicated team of volunteers.

Joining our wonderful team of Ambassadors this year are **Mike Holmes, Kirsty Budenbender, Dr Roz Stanley, Richard Green and Lucy Strong.**



Mike joins us having retired from Mesothelioma UK in his role as Senior Corporate Relations Officer. Mike has supported the charity for many years in his former roles, in the pharmaceutical and legal industry where he is very well known and has a deep understanding of this disease. Mike is keen to continue to support us by attending industry conferences on behalf of Mesothelioma UK.



Kirsty is the Director of DSK Environmental Ltd, which she runs alongside her husband, Dirk. The company was established in February 2020 and specialises in asbestos removal across both residential and commercial sectors, as well as industrial maintenance at waste-to-energy power stations. With a deep knowledge of the asbestos industry, Kirsty brings a wealth of experience from a diverse background, including banking, manufacturing, insurance services, and business development. She is passionate about leading from the front and takes every opportunity to raise awareness about the dangers of asbestos, as well as to promote the vital work of the charity.



Roz works as a Senior Project Manager at NHS England and will bring her expertise in data analysis and reporting to this role. Roz has been a supporter of the charity for many years working in the lung cancer team with our CEO Liz Darlison back in 2000 in an data/audit management role. Roz has always been interested in the underdog of cancers such as mesothelioma and lung which is why she is delighted to be able to help Mesothelioma UK in a voluntary capacity this year to get real value from the collection of patient data.



Richard is a Partner and Head of the Asbestos Litigation Team at Hugh James based in Cardiff. Richard also sits on the advisory board of the Mesothelioma UK Research Centre. Richard has a national reputation for asbestos related disease work and has specialised for over 15 years. Richard regularly provides training to specialist medical teams across the country and speaks at events accredited by the Royal College of Nurses and also Physicians.



Lucy is a Partner in the Asbestos Litigation Group at Hugh James and leads the team in Wales. Lucy has extensive experience working on complex asbestos related disease claims and regularly secures compensation awards for her clients. Lucy has acted for many mesothelioma sufferers who have had low level exposure, having previously worked in education and healthcare sectors. Lucy's national reputation within her field is testament to her position on the advisory board of the Mesothelioma UK Research Centre.

Fundraising Story



On Saturday 3 August 2024, Keira Atherton and her father Kevin took part in a sponsored skydive for Mesothelioma UK and between them have raised over £1,500.

Kiera shared, “Nine years ago, my family lost our whole world. My grandad Roy was my family’s biggest inspiration in life and we have struggled ever since his passing. Grandad Roy worked in the painting and decorating industry for the majority of his life, eventually teaching my dad to follow in his footsteps. However, through this industry my grandad was exposed to various

dangerous chemicals and fumes, one of which was known as asbestos. Asbestos can lay dormant in people’s bodies for years then cause problems later in life. Mesothelioma is what killed our amazing best friend, and we would love to help future and current sufferers of this horrific disease in battling against it. By fundraising for Mesothelioma UK, we are hoping to raise money to aid medical research into preventions, cures and treatment enhancements against mesothelioma in the hope to save someone else’s best friend. This illness is not spoken about enough, and we hope by doing this we can also raise awareness and help as much as we can to stop the battles people are facing with mesothelioma.”

Mesothelioma UK Legal Panel

Our legal panel: Expert support, advocacy, and partnership

At Mesothelioma UK, we are proud to be supported by a dedicated Legal Panel – law firms that not only offer independent legal guidance to patients and families affected by mesothelioma but also work tirelessly to raise awareness of the disease and our charity’s mission.

The panel now includes 16 UK law firms, 10 covering England and Wales, three covering Northern Ireland and three covering Scotland.

These expert legal professionals are instrumental in helping patients recover costs for treatments that may not be available on the NHS, ensuring access to care that could be crucial in the future. While the idea of making a legal claim can feel overwhelming, our Legal Panel members provide clear, compassionate, and expert advice throughout the process. There is no cost to patients or their families, and every effort is made to minimise any stress or disruption during what is already a difficult time.

Beyond legal guidance, our Legal Panel firms are vital ambassadors of Mesothelioma UK. They help us reach more people by promoting our services including gifts in Wills and our free Will-writing service which some of our members provide, and also by supporting our work through sponsorship and fundraising. Their contributions enable us to fund specialist nurses and their education. In addition, they support and sponsor key events like our Patient and Carer Day, Awards Evening, and Ladies’ Lunch, and continue to support vital awareness campaigns.

We are incredibly grateful for their continued commitment and the difference they make in the lives of the people we support.

Corporate Partners

Working together: Our corporate partners and supporters

We are proud of the strong relationships we have built with our Corporate Partners and Supporters.

Their invaluable contributions help support our mission and our work for those diagnosed and living with mesothelioma.

Our partners and supporters contribute and support the charity in many ways, from monthly donations which is a vital source of income helping us to plan for the future enabling us to increase our specialist nursing team, to participating in Mesothelioma UK’s events and campaigns or choosing us as their charity of the year. They organise fundraisers, like quizzes, balls, team building events, coffee mornings, bake sales, dress down day and much more, all helping to raise much needed awareness and funds. We are incredibly grateful for their ongoing commitment and support, helping us make a real difference for those affected by mesothelioma.



Our Corporate Relations Team is dedicated to strengthening our existing partnerships and building on and welcoming new ones in the year ahead.

To learn more about becoming a Corporate Partner or Supporter visit our website at Mesothelioma UK www.mesothelioma.uk.com/partner-with-us or contact us corporate@mesothelioma.uk.com for more information.

Gifts in Wills


We are a national charity dedicated to supporting people affected by mesothelioma through expert care, information, and advocacy.

One way to support those affected with mesothelioma is to consider leaving a gift in your Will. This year we were honoured to receive **£211,351** from 14 incredible supporters who left a gift in their Will. This could fund eight clinical nurse specialists in hospitals around the UK for one year.

To make this process simple and accessible, Mesothelioma UK continues to partner with several trusted firms from our Legal Panel to offer a free Will-writing service. There is absolutely no obligation to include a charitable gift, but we warmly encourage individuals to consider supporting Mesothelioma UK in this amazing way and create meaningful change in someone's life.

Join those who have already used this easy and free service, like Dawn McKinley who said "The free Wills service was such an easy process, no stress, just good, sound advice culminating in a fully written Will. It is such a relief to know that my wishes are officially documented. Thank you, Mesothelioma UK for providing this excellent service".

If you would like to learn more about our free Will service or leaving a gift in your Will to Mesothelioma UK, please call us on **0800 169 2409** to request your complimentary guide, or request one online here – www.mesothelioma.uk.com/leave-a-gift-in-your-will.



Patient
Carer Day
158

Community
Dinner
124

Ladies
Lunch
178

Total number of
event attendees
460

Events



Patient and Carer Day

PCD & Community Dinner: Bringing the mesothelioma community together

**This year marked the 19th annual
Mesothelioma UK Patient and Carer Day,
which was held on 10 October 2024 in Leeds.**

This event is an invaluable opportunity for patients, carers, family members, nurses, healthcare professionals, legal panel members and others to come together, share experiences and learn about the latest research and care for those affected by mesothelioma.

Topics covered by expert speakers included:

- The work of our Mesothelioma UK nurses
- An update on benefits
- Diagnosis and treatment of peritoneal mesothelioma
- Updates on research studies and clinical trials
- Mesothelioma UK short courses
- The importance of diet for mesothelioma patients



Stories from patients and their families included:



Sue Farrall, a keen marathon runner and weightlifter, shared her personal story of being diagnosed with mesothelioma two years ago.

Now a passionate volunteer and fundraiser, Sue and her group, the *Magnificent Seven*, recently completed a walking marathon raising over £10,000 for Mesothelioma UK.



Michelle Spencer shared her emotional story of how a job, taken in her youth, led to asbestos exposure, resulting in mesothelioma 45 years later.

"Life is so much more important to me. I appreciate every day. I love my family; I have wonderful friends, and I love life so much. I look at every day as another day to make memories. You have no idea what is round the corner."



As a carer, **Gail Hillson** shared *Our Journey* including her and her husband's experience of the Mesothelioma UK Carers Course and the value of our Support Groups.

The event welcomed around 160 attendees, including patients, carers and family members – all part of the wider mesothelioma community we are so proud to support.

Having listened to feedback from previous events, our Community Dinner was held the evening before the Patient Carer Day. This was an opportunity for patients, carers, our nurse team, our legal panel lawyers and the Mesothelioma UK team to share an evening together over dinner with no speakers, just time to meet, share stories and chat.



Ladies Lunch 2024

A Celebration of Strength, Solidarity, and Action

On 7 March 2025, we were thrilled to host our 5th annual Ladies Lunch at the elegant Manchester Marriott Victoria and Albert Hotel – a meaningful event held in honour of International Women’s Day.

This year’s theme, Accelerate Action, focused on advancing gender equality and building safer, more inclusive environments for everyone. The afternoon brought together supporters, professionals, and patients for a powerful celebration of resilience, advocacy, and change.

Guests were treated to a delicious three course lunch, alongside an inspiring programme of speakers. Professionals from the asbestos removal industry shared how the landscape is improving for women in their field, while also addressing the urgent issue of preventing asbestos from entering landfill – a topic with profound implications for public health and safety.

One of the most moving moments of the day came from Emily-Jane Scandrett, a young mother of three, who was diagnosed with mesothelioma at just 40. Her courageous story and hopes for future change left a lasting impact on everyone in the room.

The event was a beautiful blend of heartfelt storytelling, connection, and shared purpose – a true celebration of the strength of women affected by mesothelioma and those working to create a safer world.



Total individual
donations
£94,520.93

52

Tribute pages
opened in
memory of
loved ones

354

Online shop
orders

How We Raised the Funds

Donations for
Specific Funds

£36,700

Individual Giving

£518,764

Corporate & Trust

£66,639

Grants

£440,733

Major Donors

£40,000

Campaigns
& Challenges

£55,731

Legacies

£196,351

Events

£17,139

Non Charitable
Trading Activities

£241,534

Primary Trading

£30,481

Donated Services
& Facilities


£25,000

Investment

£43,582

Rental

£4,260



TOTAL:
£1,716,914

How We Spent the Funds

Income Generation

£254,018

Patient Support

£846,997

Admin & Operational

£232,247

Research & Audit


£160,972

Awareness

£46,535

Information Costs

£60,815



TOTAL:

£1,601,584

Trustees Report

The trustees present their report with the financial statements of Mesothelioma UK CIO for the year ended 31 March 2024. (The financial statements can be found at www.mesothelioma.uk.com/accounts-and-reports).

The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Structure, Governance and Management

Governing Document

Since re-registering in 2018, the charity has operated with a constitution and the income and property of the charity shall be applied solely towards the promotion of its objects as set out in its constitution.

Status

The organisation is a Charitable Incorporated Organisation. Launched as a resource centre in 2004 it became a Charitable Trust in 2008 and re-registered as a Charitable Incorporated Organisation in 2018.

Reference and administration details of the Charity, its trustees and advisors

Charity Number

1177039

Company Number

12541690

Principal Office

235 Loughborough Road, Mountsorrel, Loughborough, LE12 7AS

Trustees

Dr N Maskell (Chair)
A L Coates
Prof K Blyth
Lorraine Creech
Simon Purves
Amanda Jones (appointed 16/9/24)
Kate Williams (appointed 16/9/24)
Craig Evans (appointed 16/9/24)
Mike Lind (appointed 16/9/24)
H Childs (resigned 27/3/24)
M Waters (resigned 25/6/24)
Dawn McKinley (resigned 2/12/24)

Chief Executive Officer

Liz Darlison

Operational Team

Tracey Calvert, Head of Finance
Alyshia Riley, Head of Fundraising & Communications
Beth Colbert, Head of Operations
Leah Taylor, Head of Nursing
Jill Lemon, Corporate Relations and Fundraising Manager
Megan Huxtable, Community Fundraising Manager
Julie Morton, Support Services Officer
Roland Ungood-Thomas, Creative Designer
Leah Scrimshire, Supporter Care Administrator
Dumitrita Gulian, Finance Officer
Charlotte Mason, Administrative Assistant
Claire Reeves, Benefits Officer
Angela Kingston-Nash, Benefits Officer
Katrina Sansone-Richmond, Marketing & Communications Officer
Neil Overall, Fundraising Manager
Beverley Forrester, Housekeeper
Mollie Shields, Corporate Fundraising Manager (Resigned May 2024)
Hazel Curtis, Finance Officer (Resigned May 2024)
Mike Holmes, Senior Corporate Relations Officer (Resigned July 2024)
Justine Bates, Individual Giving & Marketing Manager (Resigned March 2025)

Independent Auditors

Mark J Rees LLP Chartered Accountants and Statutory Auditors, Granville Hall, Granville Road, Leicester, LE1 7RU

Investment Advisors

Magma Wealth Management Limited, Magma House, 16 Davy Court, Castle Mound Way, Rugby, CV23 0UZ

Subsidiaries and Related Parties

The Mesothelioma UK Trading Company was incorporated on 31 March 2020 with company number 12541690. It is the sole subsidiary of Mesothelioma UK and exists to raise trading income for the charity. All of its profits were transferred to the charity.

Financial Overview

Basis for Preparation

The Trustees assess whether the use of the going concern concept is appropriate, i.e. whether there are any material uncertainties related to events or conditions that may cast significant doubt over the ability of the group to continue as a going concern. The Trustees make this assessment in respect of a period of at least one year from the date of authorisation for issue of the financial statements and have concluded that the group has adequate resources to continue in operational existence for the foreseeable future and there are no material uncertainties about the group's ability to continue as a going concern, thus they continue to adopt the going concern basis of accounting in preparing the financial statements.

Financial Overview

Mesothelioma UK's income is entirely dependent on donations, legacies, and grants. These contributions are crucial for funding the charity's research, support services, and awareness initiatives.

Gross income increased on the previous year and the charity managed to achieve a small increase in reserves at year end. The final amount raised over the year was £1,716,914 (2024 – £1,771,508).

Mesothelioma UK remains indebted to our charity partners who have provided significant funds toward the charity's team of specialist nurses, benefits advisor and two of our research projects. A total of £433,823 was raised through these partners towards the cost of funding these areas.

Expenditure decreased from £1,658,494 in 2023/24 to £1,601,584 in 2024/25. Spending on charitable activities was £347,566, a decrease of 4.7% on the previous year. As in previous years, the largest expenditure was on the patient support pillar, which is mainly comprised of the funding of specialist nursing posts.

More detail on how we raised and spent the funds can be seen in the charts on pages 35 and 36.

To ensure the charity's long-term financial sustainability, and with guidance from expert fundraising consultants, we have undertaken a comprehensive review of Mesothelioma UK's fundraising strategies and resources. This has informed the development of a robust long-term plan aimed at significantly enhancing the charity's income-generating capacity.

For 2024/25 the overall costs of raising funds were 14.8% of the total income (2024 – 13.7%) – similar to pre-pandemic levels. Going forward the need to invest in fundraising is essential to enable Mesothelioma UK to continue to expand its services.

Risks

Day-to-day risks for the charity are identified, treated, or managed and then monitored by the operational team. Those that pose the greatest threat to the charity are raised with the board of trustees.

Reserves

As an organisation relying almost entirely on fundraising income, our policy is to hold adequate reserves to enable us to react to any unexpected adverse events.

Mesothelioma UK's reserves policy states that unrestricted reserves should cover, at a minimum, six months operating and research centre costs, three-month costs of our contractual liabilities and also to enable us to fulfil all our research project costs.

As of 31 March 2025, the minimum unrestricted reserves were £575,118 (31 March 2024 – £626,148) and the actual level of unrestricted reserves, excluding the value of tangible fixed assets, held by the charity was £1,039,499 (31 March 2023 – £912,911).

Investments

Our investment portfolio is managed by Magma Wealth Management. As at the 31 March 2025 the portfolio stood at £544,640 This includes £532,503 of invested assets and £12,137 of cash. The value has reduced from last year due to the £250,000 withdrawal on the 9/9/25. It was decided to hold more in cash to ensure the financial security of the charity.

The investment managers brief is to manage the portfolio within agreed risk tolerance to produce long term growth in excess of Bank of England base rate plus 4% pa whilst investing in “ethical investments”, i.e. excluding specific sectors deemed to be causing harm and positively investing in companies who are seen to be benefiting the world. 2024 was a slightly positive year for investment with virtually all asset classes contributing to performance within the portfolio. Interest rates looked to be reducing globally albeit slowly which should boost asset prices.

These investments are, however, designated for long-term investing and if we review the overall portfolio strategy over a longer period of time, the portfolio is in a positive territory.

Ethical investments have again tended to underperform the general market over the last 12 months, as they are seen to be more growth orientated and are generally more sensitive to higher interest rates. More traditional industries such as banks, defense and oils fared better.

Over the longer term it is believed ethical investments still offer better prospects to outperform the wider market, **it is the future**, but are likely to be more volatile due to the concentration on a narrower band of investments.

Funds Held as Custodian

The charity holds funds on behalf of the UK Mesothelioma Alliance of £0 (2024 – £1,334).

Statements of Trustees Responsibilities

The trustees are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the group and the charity and of the incoming resources and application of resources, including the income and expenditure, for that period. In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the group and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the CIO trust deed/constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant audit information of which the group's auditors are unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

Auditors

The auditors, Mark J Rees LLP Chartered Accountants, will be proposed for re-appointment at the forthcoming Annual General Meeting.

Approved by order of the board of trustees on 1 December 2025 and signed on its behalf by:



S Purves, Trustee

Looking Forward

From the Chair of the Trustees Board



Mesothelioma UK is emerging from a period of tightening our belt through reviewing, prioritising and restructuring.

The vision and focus of the charity have never wavered – our engagement and dedication to patients providing a clear direction for the team to follow. It has been a challenging period but a privilege to work with the charity's operational team over the last few years. I feel confident and optimistic for the next few years.

The year ahead will see the team maintaining all of the amazing services that the charity provides, from information, support groups, the telephone support line, the website, social media groups, clinical trials app, benefits advice and of course, our amazing nurse team. Growth of these services will all depend on the charity's financial position. We are keen to increase our presence in every region of the UK. There are seven NHS Cancer Alliances without a Mesothelioma UK Nurse, and we have new services in Wales and Northern Ireland that we must sustain.

Mesothelioma UK has funds, thanks to a generous grant and fundraising family, that are ring fenced to support the development of our NHS mesothelioma clinical teams. The charity has been a pivotal stakeholder in the development of the Scottish Mesothelioma Network and we are working on ways to help replicate this hugely successful clinical model across the UK.


Several years ago, the charity funded a national clinical audit in mesothelioma. Demand for this to be rekindled is growing, with clinical

teams across the UK reaching out to Mesothelioma UK. We know 'if you cannot measure it, you cannot improve it'. The charity is exploring ways and means to relaunch a comprehensive national clinical audit and is working closely with clinical teams to design the approach and content that would be most beneficial for patients.

I would like to pass on a personal thank you to the Mesothelioma UK team and particularly, my fellow trustees, for their support. From us all, please know how grateful we are to all the individuals, families, companies and groups that support, donate and fundraise for Mesothelioma UK. This is an exceptional charity. immersed in an even more exceptional community of people. Chairing the Board is a privilege and I hope this year, will see the charity's reach and impact stride forward.

A handwritten signature in black ink that reads 'Nick Maskell'.

Prof N Maskell
Chair of the Trustees Board

A person with long brown hair, seen from the back, wearing a light blue t-shirt. The t-shirt features a circular logo with the text 'MESOTHELIOMA UK' and a colorful floral pattern. The background is blurred, showing other people in a room.

Mesothelioma UK could not do any of this without the ongoing support of our fundraisers, donors, corporate partners and legacies. Please continue to do all you do for the charity, it is your contribution that enables us to reach out and to do all we can to help those living with mesothelioma.



Mesothelioma UK Charitable Incorporated Organisation

Freephone: 0800 169 2409

Email: info@mesothelioma.uk.com

www.mesothelioma.uk.com

Registered Charity Number 1177039

AUDITED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
FOR
MESOTHELIOMA UK CHARITABLE INCORPORATED
ORGANISATION

Mark J Rees LLP Chartered Accountants
and Statutory Auditors
Granville Hall
Granville Road
Leicester
LE1 7RU

**MESOTHELIOMA UK CHARITABLE INCORPORATED
ORGANISATION**

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

	Page
Report of the Independent Auditors	1 to 4
Consolidated Statement of Financial Activities	5
Consolidated Balance Sheet	6
Charity Balance Sheet	7
Consolidated Cash Flow Statement	8
Notes to the Consolidated Cash Flow Statement	9
Notes to the Consolidated Financial Statements	10 to 27
Detailed Consolidated Statement of Financial Activities	28 to 30

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

Opinion

We have audited the financial statements of Mesothelioma UK Charitable Incorporated Organisation (the 'parent charity') and its subsidiaries (the 'group') for the year ended 31 March 2025 which comprise the Consolidated Statement of Financial Activities, the Consolidated Balance Sheet, the Charity Balance Sheet, the Consolidated Cash Flow Statement and Consolidated notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and of the parent charity's affairs as at 31 March 2025 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- the group has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the groups and parent charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the parent or parent charity or to cease operations, or have no realistic alternative but to do so.

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

Our responsibilities for the audit of the financial statements

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities outlined above, to detect material misstatements in respect of irregularities, including fraud. Owing to the inherent limitations of an audit, there is an unavoidable risk that material misstatements in the financial statements may not be detected, even though the audit is properly planned and performed in accordance with ISA's (UK).

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

We obtained an understanding of the legal and regulatory frameworks applicable to the group and the parent charity and industry in which it operates through our general commercial experience. We determined that the following laws and regulations were most significant: Charities SORP (FRS 102).

We enquired of management concerning the group's and parent charity's policies and procedures relating to:

- the identification and compliance with laws and regulations.
- the detection and response to the risks of fraud.
- the internal controls inherent within the group and parent charity to mitigate fraud risk and non-compliance to laws and regulations.

We enquired of management, whether they were aware of any instances of non-compliance with laws and regulations or whether they had any knowledge of actual, suspected or alleged fraud.

We communicated relevant laws and regulations and potential areas of fraud to all audit team members. We remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

We have determined that the principal risk areas where material irregularities could occur were related to posting manual journal entries to manipulate financial performance, income recognition and significant one-off or unusual transactions.

Our audit procedures were designed to respond in particular to these identified risks (including non-compliance with laws and regulations and fraud).

Our audit procedures included but were not limited to:

- A review of a sample of sales invoices and monies received from the income streams to ensure income has been accurately recorded and to confirm amounts are recognised in the correct period.
- A review of laws and regulations the charity is subject to, followed by compliance checks and discussion with management to ensure no instances of non-compliance.
- Addressing the risks of fraud through management override of controls by performing a journal entry test.

We did not identify any matters during the course of our work that indicated non-compliance with laws and regulations or relating to fraud.

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Mark J Rees LLP

Mark J Rees LLP Chartered Accountants
and Statutory Auditors

Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006

Granville Hall

Granville Road

Leicester

LE1 7RU

Date: *15/12/25*

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

	Notes	Unrestricted fund £	Restricted funds £	2025 Total funds £	2024 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations, grants and legacies	3	879,605	517,452	1,397,057	1,532,402
Charitable activities - primary trading income	7	5,481	25,000	30,481	5,268
Other trading activities	4	241,534	-	241,534	203,225
Investment income	5	43,582	-	43,582	26,353
Other income	6	4,260	-	4,260	4,260
Total		<u>1,174,462</u>	<u>542,452</u>	<u>1,716,914</u>	<u>1,771,508</u>
EXPENDITURE ON					
Raising funds	8	242,938	11,080	254,018	243,177
Charitable activities	9				
Information Expenses		60,190	625	60,815	65,936
Awareness Costs		45,910	625	46,535	79,767
Research & Audit Costs		59,812	101,160	160,972	137,708
Patient Support Costs		413,291	433,706	846,997	873,234
Administration and operational costs		230,708	1,539	232,247	258,672
Total		<u>1,052,849</u>	<u>548,735</u>	<u>1,601,584</u>	<u>1,658,494</u>
Net gains on investments		<u>3,463</u>	<u>-</u>	<u>3,463</u>	<u>60,065</u>
NET INCOME/(EXPENDITURE)		125,076	(6,283)	118,793	173,079
RECONCILIATION OF FUNDS					
Total funds brought forward		<u>925,220</u>	<u>358,065</u>	<u>1,283,285</u>	<u>1,110,206</u>
TOTAL FUNDS CARRIED FORWARD		<u><u>1,050,296</u></u>	<u><u>351,782</u></u>	<u><u>1,402,078</u></u>	<u><u>1,283,285</u></u>

The notes form part of these financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION


CONSOLIDATED BALANCE SHEET 31 MARCH 2025

	Notes	Unrestricted fund £	Restricted funds £	2025 Total funds £	2024 Total funds £
FIXED ASSETS					
Tangible assets	17	10,796	-	10,796	12,309
Investments	18	<u>800,279</u>	<u>-</u>	<u>800,279</u>	<u>791,075</u>
		811,075	-	811,075	803,384
CURRENT ASSETS					
Debtors	19	168,524	-	168,524	229,149
Investments	20	-	-	-	100,738
Cash at bank and in hand		<u>251,293</u>	<u>351,783</u>	<u>603,076</u>	<u>359,030</u>
		419,817	351,783	771,600	688,917
CREDITORS					
Amounts falling due within one year	21	<u>(180,597)</u>	<u>-</u>	<u>(180,597)</u>	<u>(209,016)</u>
NET CURRENT ASSETS		<u>239,220</u>	<u>351,783</u>	<u>591,003</u>	<u>479,901</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>1,050,295</u>	<u>351,783</u>	<u>1,402,078</u>	<u>1,283,285</u>
NET ASSETS		<u>1,050,295</u>	<u>351,783</u>	<u>1,402,078</u>	<u>1,283,285</u>
FUNDS	23				
Unrestricted funds				1,050,295	925,220
Restricted funds				<u>351,783</u>	<u>358,065</u>
TOTAL FUNDS				<u>1,402,078</u>	<u>1,283,285</u>

The financial statements were approved by the Board of Trustees and authorised for issue on19/11/2025.....
and were signed on its behalf by:



.....
S Purves - Trustee



.....
N Maskell - Trustee

The notes form part of these financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION


CHARITY BALANCE SHEET 31 MARCH 2025

	Notes	Unrestricted fund £	Restricted funds £	2025 Total funds £	2024 Total funds £
FIXED ASSETS					
Tangible assets	17	10,796	-	10,796	12,309
Investments	18	<u>800,280</u>	<u>-</u>	<u>800,280</u>	<u>791,076</u>
		811,076	-	811,076	803,385
CURRENT ASSETS					
Debtors	19	154,243	-	154,243	228,348
Investments	20	-	-	-	100,738
Cash at bank and in hand		<u>251,293</u>	<u>351,783</u>	<u>603,076</u>	<u>359,030</u>
		405,536	351,783	757,319	688,116
CREDITORS					
Amounts falling due within one year	21	<u>(166,317)</u>	<u>-</u>	<u>(166,317)</u>	<u>(208,216)</u>
NET CURRENT ASSETS		<u>239,219</u>	<u>351,783</u>	<u>591,002</u>	<u>479,900</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>1,050,295</u>	<u>351,783</u>	<u>1,402,078</u>	<u>1,283,285</u>
NET ASSETS		<u>1,050,295</u>	<u>351,783</u>	<u>1,402,078</u>	<u>1,283,285</u>
FUNDS	23				
Unrestricted funds				1,050,295	925,220
Restricted funds				<u>351,783</u>	<u>358,065</u>
TOTAL FUNDS				<u>1,402,078</u>	<u>1,283,285</u>

The financial statements were approved by the Board of Trustees and authorised for issue on19/11/2025.....
and were signed on its behalf by:



.....
S Purves - Trustee



.....
N Maskell - Trustee

The notes form part of these financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH 2025

	Notes	2025 £	2024 £
Cash flows from operating activities			
Cash generated from operations	1	<u>108,378</u>	<u>(2,655)</u>
Net cash provided by/(used in) operating activities		<u>108,378</u>	<u>(2,655)</u>
Cash flows from investing activities			
Purchase of tangible fixed assets		(2,910)	(3,573)
Movement in fixed asset investments		(5,742)	2,525
Movement in current asset investments		100,738	-
Interest received		<u>43,582</u>	<u>26,353</u>
Net cash provided by investing activities		<u>135,668</u>	<u>25,305</u>
Change in cash and cash equivalents in the reporting period		244,046	22,650
Cash and cash equivalents at the beginning of the reporting period		<u>359,030</u>	<u>336,380</u>
Cash and cash equivalents at the end of the reporting period		<u><u>603,076</u></u>	<u><u>359,030</u></u>

The notes form part of these financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH 2025

1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2025 £	2024 £
Net income for the reporting period (as per the Statement of Financial Activities)	118,793	173,079
Adjustments for:		
Depreciation charges	4,424	5,121
Gain on investments	(3,463)	(60,065)
Interest received	(43,582)	(26,353)
Decrease/(increase) in debtors	60,625	(106,757)
(Decrease)/increase in creditors	<u>(28,419)</u>	<u>12,320</u>
Net cash provided by/(used in) operations	<u>108,378</u>	<u>(2,655)</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.4.24 £	Cash flow £	At 31.3.25 £
Net cash			
Cash at bank and in hand	<u>359,030</u>	<u>244,046</u>	<u>603,076</u>
	<u>359,030</u>	<u>244,046</u>	<u>603,076</u>
Liquid resources			
Deposits included in cash	-	-	-
Current asset investments	<u>100,738</u>	<u>(100,738)</u>	<u>-</u>
	<u>100,738</u>	<u>(100,738)</u>	<u>-</u>
Total	<u>459,768</u>	<u>143,308</u>	<u>603,076</u>

The notes form part of these financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011.

Mesothelioma UK CIO meets the definition of a public benefit entity under FRS 102. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The group financial statements consolidate the financial statements of Mesothelioma UK CIO and its subsidiary up to 31 March 2025.

Reclassification of Prior Year Figures

The presentation of certain income categories has been revised in the current year to better reflect the nature of the charity's activities. Comparative figures have been reclassified accordingly. These changes have no impact on the net movement in funds or the financial position reported for the prior year.

Income

All income is recognised once the Group has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For legacies, entitlement is taken as the earlier of the date on which either: the Group is aware of probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Group that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the Group has been notified of the executor's intention to make a distribution. Where legacies have been notified to the Group, or the Group is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Donated services or facilities are recognised when the Group has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the Group of the time is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time is not recognised and refer to the Trustees' report for more information about their contribution.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the Group would have been willing to pay to obtain services or facilities or equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Grants are included in the Consolidated Statement of Financial Activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in then relevant funds on the Balance sheet. Where income is received in advance of entitlement of receipt, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

1. ACCOUNTING POLICIES - continued

Income - continued

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the service.

Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds. Charitable activities and Governance costs are costs incurred on the charity's operations, including support costs and costs relating to the governance of the charity apportioned to charitable activities.

Tangible fixed assets

All assets costing more than £500 are capitalised.

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of Financial Activities.

Tangible fixed assets are carried at costs, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives.

Depreciation is provided on the following bases:

Fixtures and fittings	15% reducing balance
Computer equipment	33.33% reducing balance

Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes. Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Group for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Taxation

The charity is exempt from corporation tax on its charitable activities.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

1. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits

The Group operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Group to the fund in respect of the period.

Fixed asset investments

Listed investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Consolidated statement of financial activities.

Investments in subsidiaries are valued at cost less provision for impairment.

Other investments consists of fixed term deposit accounts with high street banks and building societies that mature more than one year from the reporting date.

Interest Receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Group anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Consolidated statement of financial activities as a finance cost.

Current asset investments

Current asset investments are cash or cash equivalents with a maturity date more than three months after the reporting date but less than one year valued at cost.

Going Concern

The Trustees assess whether the use of going concern is appropriate i.e. whether there are any material uncertainties related to events or conditions that may cast significant doubt over the ability of the charity to continue as a going concern. The Trustees make this assessment in respect of a period of at least one year from the date of authorisation for issue of the financial statements and have concluded that the charity has adequate resources to continue in operational existence for the foreseeable future and there are no material uncertainties about the charity's ability to continue as a going concern, thus they continue to adopt the going concern basis of accounting in preparing the financial statements.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

2. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Useful economic lives of tangible assets

The annual depreciation charge for tangible fixed assets is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are reassessed annually. They are amended when necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and the physical condition of the assets. See note 16 for the carrying amount of the fixture and fittings and computer equipment and note 1 for the useful economic lives for each class of assets.

Residual legacies

There is some uncertainty in the value of residual legacies recognised due to the time lapse between when probate has been granted and the final distribution is made.

Donated services and facilities

The Group has been donated the use of the premises they operate from. The fair value of the donated facility has been arrived at based on the amount the Group would pay in the open market for an alternative. This has been calculated on an estimated average rate per square foot. While this is considered a reasonable reliable approach there is some uncertainty due to multiple factors affecting the rental value of the property including the size, the age and demographical area.

3. DONATIONS, GRANTS AND LEGACIES

	2025	2024
	£	£
Donations	734,973	683,612
Legacies	196,351	220,913
Grants	440,733	602,877
Donated services and facilities	<u>25,000</u>	<u>25,000</u>
	<u>1,397,057</u>	<u>1,532,402</u>

Donated services and facilities comprise of the use of the premises the Group operates from. The donation represents the deemed market rent of the property.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

3. DONATIONS, GRANTS AND LEGACIES - continued

Grants received included in the above, are as follows:

	2025 £	2024 £
Armed Forces Covenant	-	712
Readleys for provision of benefits advisor	9,733	6,736
UK Government Covid Medical Research	-	133,178
B&CE Charitable Trust for benefits advisor	15,000	-
Memorials Grant Scheme to cover Meso UK's AF Memorial VAT costs	-	4,040
Grants for the provision of nursing services from:		
HASAG	87,344	150,225
LASAG	57,379	22,000
Readleys	22,278	19,952
Mavis Nye foundation	22,000	33,000
Action on Asbestos	58,000	44,000
Asbestos Action	24,000	48,000
SWASAG	11,590	11,498
Meso UK's Legal Panel	39,337	31,124
MAPS Benevolent fund	25,000	25,000
Clydebank Asbestos Group	36,690	-
Meso UK Legal Partner	22,000	-
ASCE	5,382	-
GMAVSG	5,000	-
Grants for research projects from:		
HASAG	-	37,191
Erase-Meso	-	36,221
	440,733	602,877

4. OTHER TRADING ACTIVITIES

	2025 £	2024 £
Trading income	198,806	166,076
Events income	30,516	20,454
One Lottery income	4,242	4,242
Shop income	7,970	12,453
	241,534	203,225

The trading income represents income from Mesothelioma UK commercial relationships which includes:

- Commission from the UK National Asbestos Register
- Income raised from members of Mesothelioma UK Trading Ltd's legal panel, who make payment to Mesothelioma UK Trading Ltd, in return for the inclusion of their name and logo on our website and legal advice leaflet. Their logo is also included on the Mesothelioma Matters magazine, and they each have space for one article in one of the quarterly magazines per year.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

5. INVESTMENT INCOME

	2025	2024
	£	£
Deposit account interest	37,891	21,631
Dividends received	<u>5,691</u>	<u>4,722</u>
	<u>43,582</u>	<u>26,353</u>

6. OTHER INCOME

	2025	2024
	£	£
Rental income	<u>4,260</u>	<u>4,260</u>

7. INCOME FROM CHARITABLE ACTIVITIES

	2025	2024
	£	£
ADDRI income	25,000	-
Speakers fees	250	-
Events income	<u>5,231</u>	<u>5,268</u>
	<u>30,481</u>	<u>5,268</u>

Funds have been provided to Mesothelioma UK to cover the costs incurred supporting the Australian Dust Disease Research Institute (ADDRI) to develop resources, particularly specialist mesothelioma nursing across Australia.

8. RAISING FUNDS

Raising donations and legacies

	2025	2024
	£	£
Staff costs	140,930	124,148
Will writing	3,027	1,817
Stripe and online giving fees	15,051	11,897
Christmas card purchases	1,992	1,869
Fundraising costs	29,155	32,464
Travel expenses	182	193
Charitable events	18,152	17,639
Website and social media	3,301	3,110
Online shop expenses	1,699	3,049
UHL staff costs	36,407	43,111
Head of nursing	<u>2,485</u>	<u>2,225</u>
	<u>252,381</u>	<u>241,522</u>

Other trading expenses

	2025	2024
	£	£
Administration expenses	<u>1,637</u>	<u>1,655</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

9. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 10) £	Support costs (see note 11) £	Totals £
Information Expenses	60,815	-	60,815
Awareness Costs	46,535	-	46,535
Research & Audit Costs	160,972	-	160,972
Patient Support Costs	846,997	-	846,997
Administration and operational costs	-	232,247	232,247
	<u>1,115,319</u>	<u>232,247</u>	<u>1,347,566</u>

10. DIRECT COSTS OF CHARITABLE ACTIVITIES

	2025 £	2024 £
Staff costs	192,831	198,529
Provision for nursing services	635,825	649,660
Nurses meetings	2,795	5,200
Website and social media	13,201	12,442
Patient support sundries and other support costs	5,795	5,464
Patient travel	1,135	1,412
Printing and design magazine	4,218	-
Project Wales	140	2,438
Research centre main award	74,312	(1,639)
Other research costs	625	578
Armed Forces project expenses	-	19,611
Information expenses	6,090	11,482
Patient carer day	14,657	11,253
Awareness costs	-	1,671
Travel expenses	-	47
Team leaders	54,034	84,144
Research grants	53,095	108,289
Head of nursing	44,726	40,058
Educational event expenses	2,738	6,006
UHL staff costs	9,102	-
	<u>1,115,319</u>	<u>1,156,645</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

11. SUPPORT COSTS

	Other £	Governance costs £	Totals £
Administration and operational costs	<u>224,145</u>	<u>8,102</u>	<u>232,247</u>

Support costs, included in the above, are as follows:

	2025 £	2024 £
Wages	116,561	140,589
Social security	8,828	10,151
Pensions	8,275	9,613
Rates and water	3,449	4,709
Insurance	1,147	1,032
Telephone	3,943	3,905
Postage and stationery	1,700	1,674
Repairs and maintenance	1,880	751
Legal and professional fees	3,339	6,746
Governance	5,676	4,455
Travel expenses	87	513
Investment manager costs	5,588	6,022
Training	704	106
Subscriptions	1,938	4,888
IT support and other IT costs	12,439	10,597
CRM expenses	8,481	7,349
Marketing and adverts	4,859	2,576
Bank charges	1,265	862
Office expenses	2,077	2,159
Head of nursing	2,485	2,225
Rent	25,000	25,000
Depreciation of tangible fixed assets	4,424	5,120
Auditors' remuneration	<u>8,102</u>	<u>7,630</u>
	<u>232,247</u>	<u>258,672</u>

12. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2025 £	2024 £
Depreciation - owned assets	<u>4,423</u>	<u>5,121</u>

13. AUDITORS' REMUNERATION

	2025 £	2024 £
Fees payable to the charity's auditors for the audit of the charity's financial statements	<u>8,102</u>	<u>7,630</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

14. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2025 nor for the year ended 31 March 2024.

Trustees' expenses

For the year ended 31 March 2025, there was £nil (2024: £191) paid to Mr N Maskell and there was £115 (2024: £50) paid to Ms L Creech.

15. STAFF COSTS

	2025	2024
	£	£
Wages and salaries	403,169	420,504
Social security costs	32,964	33,685
Other pension costs	31,292	28,841
	<u>467,425</u>	<u>483,030</u>

Remuneration of key management personnel

Key management personnel are deemed to be those having authority and responsibility, delegated to them by the trustees for planning, directing and controlling the activities of the charity. The total employee benefits of the key management personnel of the charity amounted to £210,642 (2024: £112,415).

The average monthly number of employees during the year was as follows:

	2025	2024
Support staff	<u>15</u>	<u>16</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2025	2024
£70,001 - £80,000	<u>1</u>	<u>-</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

16. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - 31 MARCH 2024

	Unrestricted fund £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations, grants and legacies	888,469	643,933	1,532,402
Charitable activities - primary trading income	5,268	-	5,268
Other trading activities	203,225	-	203,225
Investment income	26,353	-	26,353
Other income	<u>4,260</u>	<u>-</u>	<u>4,260</u>
Total	<u>1,127,575</u>	<u>643,933</u>	<u>1,771,508</u>
EXPENDITURE ON			
Raising funds	243,177	-	243,177
Charitable activities			
Information Expenses	65,936	-	65,936
Awareness Costs	60,123	19,644	79,767
Research & Audit Costs	59,511	78,197	137,708
Patient Support Costs	360,705	512,529	873,234
Administration and operational costs	<u>258,672</u>	<u>-</u>	<u>258,672</u>
Total	<u>1,048,124</u>	<u>610,370</u>	<u>1,658,494</u>
Net gains on investments	<u>60,065</u>	<u>-</u>	<u>60,065</u>
NET INCOME	139,516	33,563	173,079
RECONCILIATION OF FUNDS			
Total funds brought forward	<u>785,704</u>	<u>324,502</u>	<u>1,110,206</u>
TOTAL FUNDS CARRIED FORWARD	<u>925,220</u>	<u>358,065</u>	<u>1,283,285</u>

**MESOTHELIOMA UK CHARITABLE INCORPORATED
ORGANISATION**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025**

17. TANGIBLE FIXED ASSETS – GROUP

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 April 2024	3,787	33,554	37,341
Additions	<u>-</u>	<u>2,910</u>	<u>2,910</u>
At 31 March 2025	<u>3,787</u>	<u>36,464</u>	<u>40,251</u>
DEPRECIATION			
At 1 April 2024	2,945	22,087	25,032
Charge for year	<u>126</u>	<u>4,297</u>	<u>4,423</u>
At 31 March 2025	<u>3,071</u>	<u>26,384</u>	<u>29,455</u>
NET BOOK VALUE			
At 31 March 2025	<u>716</u>	<u>10,080</u>	<u>10,796</u>
At 31 March 2024	<u>842</u>	<u>11,467</u>	<u>12,309</u>

TANGIBLE FIXED ASSETS - CHARITY

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 April 2024	3,787	33,554	37,341
Additions	<u>-</u>	<u>2,910</u>	<u>2,910</u>
At 31 March 2025	<u>3,787</u>	<u>36,464</u>	<u>40,251</u>
DEPRECIATION			
At 1 April 2024	2,945	22,087	25,032
Charge for year	<u>126</u>	<u>4,297</u>	<u>4,423</u>
At 31 March 2025	<u>3,071</u>	<u>26,384</u>	<u>29,455</u>
NET BOOK VALUE			
At 31 March 2025	<u>716</u>	<u>10,080</u>	<u>10,796</u>
At 31 March 2024	<u>842</u>	<u>11,467</u>	<u>12,309</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

18. FIXED ASSET INVESTMENTS – GROUP

	2025 £	2024 £
Shares	544,641	791,075
Other	<u>255,638</u>	<u>-</u>
	<u>800,279</u>	<u>791,075</u>

Additional information as follows:

	Listed investments £	Cash and settlements pending £	Totals £
MARKET VALUE			
At 1 April 2024	774,647	16,428	791,075
Additions	91,771	343,069	434,840
Disposals	(337,378)	(347,359)	(684,737)
Revaluations	<u>3,463</u>	<u>-</u>	<u>3,463</u>
At 31 March 2025	<u>532,503</u>	<u>12,138</u>	<u>544,641</u>
NET BOOK VALUE			
At 31 March 2025	<u>532,503</u>	<u>12,138</u>	<u>544,641</u>
At 31 March 2024	<u>774,647</u>	<u>16,428</u>	<u>791,075</u>

FIXED ASSET INVESTMENTS – CHARITY

	2025 £	2024 £
Shares	544,642	791,076
Other	<u>255,638</u>	<u>-</u>
	<u>800,280</u>	<u>791,076</u>

Additional information as follows:

	Shares in group undertakings £	Listed investments £	Cash and settlements pending £	Totals £
MARKET VALUE				
At 1 April 2024	1	774,647	16,428	791,076
Additions	-	91,771	343,069	434,840
Disposals	-	(337,378)	(347,359)	(684,737)
Revaluations	<u>-</u>	<u>3,463</u>	<u>-</u>	<u>3,463</u>
At 31 March 2025	<u>1</u>	<u>532,503</u>	<u>12,138</u>	<u>544,642</u>
NET BOOK VALUE				
At 31 March 2025	<u>1</u>	<u>532,503</u>	<u>12,138</u>	<u>544,642</u>
At 31 March 2024	<u>1</u>	<u>774,647</u>	<u>16,428</u>	<u>791,076</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

FIXED ASSET INVESTMENTS – CHARITY - continued

Cost or valuation at 31 March 2025 is represented by:

	Shares in group undertakings £	Listed investments £	Cash and settlements pending £	Totals £
Valuation in 2025	-	532,503	-	532,503
Cost	<u>1</u>	<u>-</u>	<u>12,138</u>	<u>12,139</u>
	<u><u>1</u></u>	<u><u>532,503</u></u>	<u><u>12,138</u></u>	<u><u>544,642</u></u>

The charity's investments at the balance sheet date in the share capital of companies include the following:

Mesothelioma UK Trading Limited

Registered office: 235 Loughborough Road, Mountsorrel, Loughborough, LE12 7AS

Company number: 12541690

Nature of business: Sponsorship and advertising sales

Class of share: %
holding
Ordinary 100

	2025 £	2024 £
Aggregate capital and reserves	1	1
Profit for the year	<u>197,169</u>	<u>164,421</u>

FIXED ASSET INVESTMENTS – GROUP AND CHARITY

Investments (neither listed nor unlisted) were as follows:

	2025 £	2024 £
Bank deposits	<u>255,638</u>	<u>-</u>

Other investments consists of fixed term deposit accounts with high street banks and building societies which mature in more than a year.

There were no investment assets outside the UK.

19. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR - GROUP

	2025 £	2024 £
Trade debtors	28,431	14,599
Other debtors	10,449	5,817
Prepayments and accrued income	<u>129,644</u>	<u>208,733</u>
	<u><u>168,524</u></u>	<u><u>229,149</u></u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

19. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR - CHARITY

	2025	2024
	£	£
Trade debtors	10,168	13,798
Amounts owed by group undertakings	3,982	-
Other debtors	10,449	5,817
Prepayments and accrued income	129,644	208,733
	<u>154,243</u>	<u>228,348</u>

20. CURRENT ASSET INVESTMENTS – GROUP AND CHARITY

	2025	2024
	£	£
Bank deposits	<u>-</u>	<u>100,738</u>

Current asset investments consists of fixed rate deposits with high street banks and building societies that mature more than 3 months after the reporting date but less than 12 months.

21. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR - GROUP

	2025	2024
	£	£
Trade creditors	84,241	65,983
Social security and other taxes	17,758	14,376
Other creditors	4,676	4,954
Accruals and deferred income	73,922	123,703
	<u>180,597</u>	<u>209,016</u>

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR - CHARITY

	2025	2024
	£	£
Trade creditors	84,241	65,983
Amounts owed to group undertakings	-	10,105
Social security and other taxes	9,318	9,311
Other creditors	4,676	4,954
Accruals and deferred income	68,082	117,863
	<u>166,317</u>	<u>208,216</u>

Within accruals and deferred income are funds received in advance from fundraising challenges yet to take place at the year end. The deferred income is £16,163 (2024: £11,097). The events are expected to take place in 2025/26.

22. LEASING AGREEMENTS – GROUP AND CHARITY

Minimum lease payments under non-cancellable operating leases fall due as follows:

	2025	2024
	£	£
Within one year	25,000	25,000
Between one and five years	100,000	100,000
In more than five years	37,093	62,093
	<u>162,093</u>	<u>187,093</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

23. MOVEMENT IN FUNDS

	At 1.4.24 £	Net movement in funds £	At 31.3.25 £
Unrestricted funds			
General fund	925,220	125,075	1,050,295
Restricted funds			
Grants and donations for nurses	31,881	16,277	48,158
Project NI	39,074	-	39,074
Grants and donations for research	149,183	(94,119)	55,064
Grants and donations for other restricted projects	8,653	12,624	21,277
Project Wales	19,801	(8,246)	11,555
Mick May Memorial Fund	109,473	52,599	162,072
Commonwealth Mesothelioma Research Network	-	14,583	14,583
	<u>358,065</u>	<u>(6,282)</u>	<u>351,783</u>
TOTAL FUNDS	<u><u>1,283,285</u></u>	<u><u>118,793</u></u>	<u><u>1,402,078</u></u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	1,172,825	(1,051,213)	3,463	125,075
Restricted funds				
Grants and donations for nurses	418,834	(402,557)	-	16,277
Grants and donations for research	7,041	(101,160)	-	(94,119)
Grants and donations for other restricted projects	37,968	(25,344)	-	12,624
Project Wales	1,010	(9,256)	-	(8,246)
Mick May Memorial Fund	52,599	-	-	52,599
Commonwealth Mesothelioma Research Network	25,000	(10,417)	-	14,583
	<u>542,452</u>	<u>(548,734)</u>	<u>-</u>	<u>(6,282)</u>
TOTAL FUNDS	<u><u>1,715,277</u></u>	<u><u>(1,599,947)</u></u>	<u><u>3,463</u></u>	<u><u>118,793</u></u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

23. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.4.23 £	Net movement in funds £	At 31.3.24 £
Unrestricted funds			
General fund	785,704	139,516	925,220
Restricted funds			
Grants and donations for nurses	141,276	(109,395)	31,881
Armed Forces Grant	1,474	(1,474)	-
Project NI	35,714	3,360	39,074
Grants and donations for research	-	149,183	149,183
Grants and donations for other restricted projects	24,826	(16,173)	8,653
Project Wales	11,739	8,062	19,801
Mick May Memorial Fund	109,473	-	109,473
	<u>324,502</u>	<u>33,563</u>	<u>358,065</u>
TOTAL FUNDS	<u>1,110,206</u>	<u>173,079</u>	<u>1,283,285</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	1,125,921	(1,046,470)	60,065	139,516
Restricted funds				
Grants and donations for nurses	385,747	(495,142)	-	(109,395)
Armed Forces Grant	712	(2,186)	-	(1,474)
Project NI	3,360	-	-	3,360
Grants and donations for research	206,590	(57,407)	-	149,183
Grants and donations for other restricted projects	17,023	(33,196)	-	(16,173)
Project Wales	10,500	(2,438)	-	8,062
Cost-Benefit study	20,000	(20,000)	-	-
	<u>643,932</u>	<u>(610,369)</u>	<u>-</u>	<u>33,563</u>
TOTAL FUNDS	<u>1,769,853</u>	<u>(1,656,839)</u>	<u>60,065</u>	<u>173,079</u>

Unrestricted funds are available to be spent for any purposes of the charity.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

23. MOVEMENT IN FUNDS - continued

Purposes of restricted funds

Grants and donations for nurses

Various grants and donations were received during the year towards the cost of the Mesothelioma UK clinical nurse specialists and team leaders.

Project NI

These are ring-fenced donations restricted for Mesothelioma UK to establish or expand services across Northern Ireland. Mesothelioma UK clinical nurse specialists have been recruited for Northern Ireland who will lead the development of appropriate services.

Project Wales

These are ring-fenced donations restricted for Mesothelioma UK to establish or expand services across Wales. Mesothelioma UK clinical nurse specialists have been recruited in the region who will lead the development of appropriate services.

Mick May Memorial Fund

Most of the funds in the MMMF were a grant from the Schroder Foundation. This is for use under the 'Improving Outcomes and Experience' pillar, to ensure patients have equitable access to the best treatment, care, information and support including helping to build a comprehensive multi-disciplinary team approach and evidenced based care pathways and guidelines which are fundamental to achieving improved outcomes and experiences.

Commonwealth Mesothelioma Research Network

Mesothelioma UK are supporting the Australian Dust Disease Research Institute (ADDRI) to develop resources, particularly specialist mesothelioma nursing, across Australia. In addition the two organisations have established an international research network and together they plan to develop a menu of resources and events to help share mesothelioma specific learning, expertise and knowledge across all countries in the commonwealth.

Grants for Research

Donations were received restricted for both general research and specific research projects.

Grants for other restricted projects

Other donations were received and restricted for the education of the nurses, towards the funding of Mesothelioma UK benefits advisors, towards the funding of support groups and to help towards travel costs.

24. EMPLOYEE BENEFIT OBLIGATIONS

The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Group in an independently administered fund. The pension cost charges represent the contributions payable by the charity to the fund in the year and amount to £31,292 (2024: £28,841). At the balance sheet date £4,640 (2024: £3,620) were payable to the fund and are included in creditors.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

24. CONTINGENT ASSET

The Group has been notified of an entitlement to legacies of which the Group is unable to measure reliably the value of amounts due and therefore no provision has been made in the accounts.

25. RELATED PARTY DISCLOSURES

A L Coates is a Trustee of the parent charity and a partner of Irwin Mitchell Solicitors. During the period, £64,059 (2024: £36,828) was receivable by the group from Irwin Mitchell Solicitors being £27,600 (2024: £24,000) sponsorship income plus £36,459 (2024: £12,828) from fundraising events and donations. Also, during the period, the group acquired will writing and other professional services from Irwin Mitchell Solicitors at a cost of £2,204 (2024: £1,547).

D McKinley was a Trustee of the parent charity, resigning on 31 December 2024, and Senior Executive Officer of the British Thoracic Oncology Group (BTOG). During the period, BTOG paid rent to the parent charity of £4,260 (2024: £4,260) and received amounts for recharged expenses of £360 (2024: £194).

C Evans is a Trustee of the parent charity and Chief Operating Officer at UK Asbestos Training Association Ltd (UKATA). During the period, UKATA made a donation of £30 (2024: £nil) to the parent charity.

A Jones is a Trustee of the parent charity and a partner of Thompsons Solicitors LLP. During the period, £39,909 (2024: £nil) was receivable by the group from Thompsons Solicitors LLP being £27,600 (2024: £nil) sponsorship income plus £12,309 (2024: £nil) from fundraising events and donations.

L Darlison is the Chief Executive Officer of the parent charity and Director of the trading company. During the period, No More Mist provided repairs to the group of £52 (2024: £nil), this entity is owned by Liz's spouse, S Darlison. In addition, L&E Electrical Contractors provided maintenance work of £163 (2024: £nil), in which Liz's son in law, S Lewitt, is a shareholder and director.

H Childs resigned as a Trustee of the parent charity on 27 March 2024 and is a partner of Royds Withy King Solicitors. During 2024, £28,134 was receivable by the group from Royds Withy King Solicitors being £28,134 worth of sponsorship income. As H Childs resigned in the previous accounting period there are no further related party transactions to disclose.

26. CONTRIBUTIONS OF VOLUNTEERS AND SUPPORTERS

The charity is grateful for the unstinting efforts of volunteer fundraisers who take part in a wide range of sponsored events and other fundraising activities. The vast majority of income comes from private individuals making donations, participating in sponsored events, or leaving legacies.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

DETAILED CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

	2025 £	2024 £
INCOME AND ENDOWMENTS		
Donations, grants and legacies		
Donations	734,973	683,612
Legacies	196,351	220,913
Grants	440,733	602,877
Donated services and facilities	<u>25,000</u>	<u>25,000</u>
	1,397,057	1,532,402
Income from charitable activities		
ADDRI income	25,000	-
Speaker fees	250	-
Events income	<u>5,231</u>	<u>5,268</u>
	30,481	5,268
Other trading activities		
Trading income	198,806	166,076
Events income	30,516	20,454
One Lottery income	4,242	4,242
Shop income	<u>7,970</u>	<u>12,453</u>
	241,534	203,225
Investment income		
Deposit account interest	37,891	21,631
Dividends received	<u>5,691</u>	<u>4,722</u>
	43,582	26,353
Other income		
Rental income	<u>4,260</u>	<u>4,260</u>
Total incoming resources	1,716,914	1,771,508
EXPENDITURE		
Raising donations and legacies		
Wages	120,980	108,463
Social security	9,958	8,294
Pensions	9,992	7,391
Will writing	3,027	1,817
Stripe and online giving fees	15,051	11,897
Christmas card purchases	1,992	1,869
Fundraising costs	29,155	32,464
Travel expenses	182	193
Charitable events	18,152	17,639
Website and social media	3,301	3,110
Online shop expenses	1,699	3,049
UHL staff costs	36,407	43,111
Head of nursing	<u>2,485</u>	<u>2,225</u>
	252,381	241,522

This page does not form part of the statutory financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

DETAILED CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

	2025 £	2024 £
Other trading expenses		
Administration expenses	1,637	1,655
Charitable activities		
Wages	165,628	171,452
Social security	14,178	15,240
Pensions	13,025	11,837
Provision for nursing services	635,825	649,660
Nurses meetings	2,795	5,200
Website and social media	13,201	12,442
Patient support sundries and other support costs	5,795	5,464
Patient travel	1,135	1,412
Printing and design magazine	4,218	-
Project Wales	140	2,438
Research centre main award	74,312	(1,639)
Other research costs	625	578
Armed Forces project expenses	-	19,611
Information expenses	6,090	11,482
Patient carer day	14,657	11,253
Awareness costs	-	1,671
Travel expenses	-	47
Team leaders	54,034	84,144
Research grants	53,095	108,289
Head of nursing	44,726	40,058
Educational event expenses	2,738	6,006
UHL staff costs	9,102	-
	1,115,319	1,156,645
Support costs		
Other		
Wages	116,561	140,589
Social security	8,828	10,151
Pensions	8,275	9,613
Rates and water	3,449	4,709
Insurance	1,147	1,032
Telephone	3,943	3,905
Postage and stationery	1,700	1,674
Repairs and maintenance	1,880	751
Legal and professional fees	3,339	6,746
Governance	5,676	4,455
Travel expenses	87	513
Investment manager costs	5,588	6,022
Training	704	106
Subscriptions	1,938	4,888
IT support and other IT costs	12,439	10,597
CRM expenses	8,481	7,349
Carried forward	184,035	213,100

This page does not form part of the statutory financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

	2025 £	2024 £
Other		
Brought forward	184,035	213,100
Marketing and adverts	4,859	2,576
Bank charges	1,265	862
Office expenses	2,077	2,159
Head of nursing	2,485	2,224
Rent	25,000	25,000
Depreciation of tangible fixed assets	4,424	5,121
	<u>224,145</u>	<u>251,042</u>
Governance costs		
Auditors' remuneration	<u>8,102</u>	<u>7,630</u>
Total resources expended	<u>1,601,584</u>	<u>1,658,494</u>
Net income before gains and losses	115,330	113,014
Realised recognised gains and losses		
Realised gains/(losses) on fixed asset investments	<u>3,463</u>	<u>60,065</u>
Net income	<u><u>118,793</u></u>	<u><u>173,079</u></u>

This page does not form part of the statutory financial statements

AUDITED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025
FOR
MESOTHELIOMA UK CHARITABLE INCORPORATED
ORGANISATION

Mark J Rees LLP Chartered Accountants
and Statutory Auditors
Granville Hall
Granville Road
Leicester
LE1 7RU

**MESOTHELIOMA UK CHARITABLE INCORPORATED
ORGANISATION**

**CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2025**

	Page
Report of the Independent Auditors	1 to 4
Consolidated Statement of Financial Activities	5
Consolidated Balance Sheet	6
Charity Balance Sheet	7
Consolidated Cash Flow Statement	8
Notes to the Consolidated Cash Flow Statement	9
Notes to the Consolidated Financial Statements	10 to 27
Detailed Consolidated Statement of Financial Activities	28 to 30

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

Opinion

We have audited the financial statements of Mesothelioma UK Charitable Incorporated Organisation (the 'parent charity') and its subsidiaries (the 'group') for the year ended 31 March 2025 which comprise the Consolidated Statement of Financial Activities, the Consolidated Balance Sheet, the Charity Balance Sheet, the Consolidated Cash Flow Statement and Consolidated notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the group's and of the parent charity's affairs as at 31 March 2025 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group's and the parent charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- the group has not kept adequate accounting records; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the groups and parent charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the parent or parent charity or to cease operations, or have no realistic alternative but to do so.

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

Our responsibilities for the audit of the financial statements

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities outlined above, to detect material misstatements in respect of irregularities, including fraud. Owing to the inherent limitations of an audit, there is an unavoidable risk that material misstatements in the financial statements may not be detected, even though the audit is properly planned and performed in accordance with ISA's (UK).

The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

We obtained an understanding of the legal and regulatory frameworks applicable to the group and the parent charity and industry in which it operates through our general commercial experience. We determined that the following laws and regulations were most significant: Charities SORP (FRS 102).

We enquired of management concerning the group's and parent charity's policies and procedures relating to:

- the identification and compliance with laws and regulations.
- the detection and response to the risks of fraud.
- the internal controls inherent within the group and parent charity to mitigate fraud risk and non-compliance to laws and regulations.

We enquired of management, whether they were aware of any instances of non-compliance with laws and regulations or whether they had any knowledge of actual, suspected or alleged fraud.

We communicated relevant laws and regulations and potential areas of fraud to all audit team members. We remained alert to any indications of fraud or non-compliance with laws and regulations throughout the audit.

We have determined that the principal risk areas where material irregularities could occur were related to posting manual journal entries to manipulate financial performance, income recognition and significant one-off or unusual transactions.

Our audit procedures were designed to respond in particular to these identified risks (including non-compliance with laws and regulations and fraud).

Our audit procedures included but were not limited to:

- A review of a sample of sales invoices and monies received from the income streams to ensure income has been accurately recorded and to confirm amounts are recognised in the correct period.
- A review of laws and regulations the charity is subject to, followed by compliance checks and discussion with management to ensure no instances of non-compliance.
- Addressing the risks of fraud through management override of controls by performing a journal entry test.

We did not identify any matters during the course of our work that indicated non-compliance with laws and regulations or relating to fraud.

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charitable company's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Mark J Rees LLP

Mark J Rees LLP Chartered Accountants
and Statutory Auditors

Eligible to act as an auditor in terms of Section 1212 of the Companies Act 2006

Granville Hall

Granville Road

Leicester

LE1 7RU

Date: *15/12/25*

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

	Notes	Unrestricted fund £	Restricted funds £	2025 Total funds £	2024 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations, grants and legacies	3	879,605	517,452	1,397,057	1,532,402
Charitable activities - primary trading income	7	5,481	25,000	30,481	5,268
Other trading activities	4	241,534	-	241,534	203,225
Investment income	5	43,582	-	43,582	26,353
Other income	6	4,260	-	4,260	4,260
Total		<u>1,174,462</u>	<u>542,452</u>	<u>1,716,914</u>	<u>1,771,508</u>
EXPENDITURE ON					
Raising funds	8	242,938	11,080	254,018	243,177
Charitable activities	9				
Information Expenses		60,190	625	60,815	65,936
Awareness Costs		45,910	625	46,535	79,767
Research & Audit Costs		59,812	101,160	160,972	137,708
Patient Support Costs		413,291	433,706	846,997	873,234
Administration and operational costs		230,708	1,539	232,247	258,672
Total		<u>1,052,849</u>	<u>548,735</u>	<u>1,601,584</u>	<u>1,658,494</u>
Net gains on investments		<u>3,463</u>	<u>-</u>	<u>3,463</u>	<u>60,065</u>
NET INCOME/(EXPENDITURE)		125,076	(6,283)	118,793	173,079
RECONCILIATION OF FUNDS					
Total funds brought forward		<u>925,220</u>	<u>358,065</u>	<u>1,283,285</u>	<u>1,110,206</u>
TOTAL FUNDS CARRIED FORWARD		<u><u>1,050,296</u></u>	<u><u>351,782</u></u>	<u><u>1,402,078</u></u>	<u><u>1,283,285</u></u>

The notes form part of these financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION


CONSOLIDATED BALANCE SHEET 31 MARCH 2025

	Notes	Unrestricted fund £	Restricted funds £	2025 Total funds £	2024 Total funds £
FIXED ASSETS					
Tangible assets	17	10,796	-	10,796	12,309
Investments	18	800,279	-	800,279	791,075
		811,075	-	811,075	803,384
CURRENT ASSETS					
Debtors	19	168,524	-	168,524	229,149
Investments	20	-	-	-	100,738
Cash at bank and in hand		251,293	351,783	603,076	359,030
		419,817	351,783	771,600	688,917
CREDITORS					
Amounts falling due within one year	21	(180,597)	-	(180,597)	(209,016)
NET CURRENT ASSETS		239,220	351,783	591,003	479,901
TOTAL ASSETS LESS CURRENT LIABILITIES		1,050,295	351,783	1,402,078	1,283,285
NET ASSETS		1,050,295	351,783	1,402,078	1,283,285
FUNDS	23				
Unrestricted funds				1,050,295	925,220
Restricted funds				351,783	358,065
TOTAL FUNDS				1,402,078	1,283,285

The financial statements were approved by the Board of Trustees and authorised for issue on19/11/2025.....
and were signed on its behalf by:



.....
S Purves - Trustee



.....
N Maskell - Trustee

The notes form part of these financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION


CHARITY BALANCE SHEET 31 MARCH 2025

	Notes	Unrestricted fund £	Restricted funds £	2025 Total funds £	2024 Total funds £
FIXED ASSETS					
Tangible assets	17	10,796	-	10,796	12,309
Investments	18	<u>800,280</u>	<u>-</u>	<u>800,280</u>	<u>791,076</u>
		811,076	-	811,076	803,385
CURRENT ASSETS					
Debtors	19	154,243	-	154,243	228,348
Investments	20	-	-	-	100,738
Cash at bank and in hand		<u>251,293</u>	<u>351,783</u>	<u>603,076</u>	<u>359,030</u>
		405,536	351,783	757,319	688,116
CREDITORS					
Amounts falling due within one year	21	<u>(166,317)</u>	<u>-</u>	<u>(166,317)</u>	<u>(208,216)</u>
NET CURRENT ASSETS		<u>239,219</u>	<u>351,783</u>	<u>591,002</u>	<u>479,900</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>1,050,295</u>	<u>351,783</u>	<u>1,402,078</u>	<u>1,283,285</u>
NET ASSETS		<u>1,050,295</u>	<u>351,783</u>	<u>1,402,078</u>	<u>1,283,285</u>
FUNDS	23				
Unrestricted funds				1,050,295	925,220
Restricted funds				<u>351,783</u>	<u>358,065</u>
TOTAL FUNDS				<u>1,402,078</u>	<u>1,283,285</u>

The financial statements were approved by the Board of Trustees and authorised for issue on19/11/2025.....
and were signed on its behalf by:



.....
S Purves - Trustee



.....
N Maskell - Trustee

The notes form part of these financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH 2025

	Notes	2025 £	2024 £
Cash flows from operating activities			
Cash generated from operations	1	<u>108,378</u>	<u>(2,655)</u>
Net cash provided by/(used in) operating activities		<u>108,378</u>	<u>(2,655)</u>
Cash flows from investing activities			
Purchase of tangible fixed assets		(2,910)	(3,573)
Movement in fixed asset investments		(5,742)	2,525
Movement in current asset investments		100,738	-
Interest received		<u>43,582</u>	<u>26,353</u>
Net cash provided by investing activities		<u>135,668</u>	<u>25,305</u>
Change in cash and cash equivalents in the reporting period		244,046	22,650
Cash and cash equivalents at the beginning of the reporting period		<u>359,030</u>	<u>336,380</u>
Cash and cash equivalents at the end of the reporting period		<u><u>603,076</u></u>	<u><u>359,030</u></u>

The notes form part of these financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH 2025

1. RECONCILIATION OF NET INCOME TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2025 £	2024 £
Net income for the reporting period (as per the Statement of Financial Activities)	118,793	173,079
Adjustments for:		
Depreciation charges	4,424	5,121
Gain on investments	(3,463)	(60,065)
Interest received	(43,582)	(26,353)
Decrease/(increase) in debtors	60,625	(106,757)
(Decrease)/increase in creditors	<u>(28,419)</u>	<u>12,320</u>
Net cash provided by/(used in) operations	<u>108,378</u>	<u>(2,655)</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.4.24 £	Cash flow £	At 31.3.25 £
Net cash			
Cash at bank and in hand	<u>359,030</u>	<u>244,046</u>	<u>603,076</u>
	<u>359,030</u>	<u>244,046</u>	<u>603,076</u>
Liquid resources			
Deposits included in cash	-	-	-
Current asset investments	<u>100,738</u>	<u>(100,738)</u>	<u>-</u>
	<u>100,738</u>	<u>(100,738)</u>	<u>-</u>
Total	<u>459,768</u>	<u>143,308</u>	<u>603,076</u>

The notes form part of these financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2025

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011.

Mesothelioma UK CIO meets the definition of a public benefit entity under FRS 102. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value, as modified by the revaluation of certain assets.

The group financial statements consolidate the financial statements of Mesothelioma UK CIO and its subsidiary up to 31 March 2025.

Reclassification of Prior Year Figures

The presentation of certain income categories has been revised in the current year to better reflect the nature of the charity's activities. Comparative figures have been reclassified accordingly. These changes have no impact on the net movement in funds or the financial position reported for the prior year.

Income

All income is recognised once the Group has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

For legacies, entitlement is taken as the earlier of the date on which either: the Group is aware of probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Group that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the Group has been notified of the executor's intention to make a distribution. Where legacies have been notified to the Group, or the Group is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Donated services or facilities are recognised when the Group has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the Group of the time is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time is not recognised and refer to the Trustees' report for more information about their contribution.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the Group would have been willing to pay to obtain services or facilities or equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Grants are included in the Consolidated Statement of Financial Activities on a receivable basis. The balance of income received for specific purposes but not expended during the period is shown in then relevant funds on the Balance sheet. Where income is received in advance of entitlement of receipt, its recognition is deferred and included in creditors as deferred income. Where entitlement occurs before income is received, the income is accrued.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

1. ACCOUNTING POLICIES - continued

Income - continued

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

Other income is recognised in the period in which it is receivable and to the extent the goods have been provided or on completion of the service.

Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds. Charitable activities and Governance costs are costs incurred on the charity's operations, including support costs and costs relating to the governance of the charity apportioned to charitable activities.

Tangible fixed assets

All assets costing more than £500 are capitalised.

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of Financial Activities.

Tangible fixed assets are carried at costs, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives.

Depreciation is provided on the following bases:

Fixtures and fittings	15% reducing balance
Computer equipment	33.33% reducing balance

Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Group and which have not been designated for other purposes. Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Group for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Taxation

The charity is exempt from corporation tax on its charitable activities.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

1. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits

The Group operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Group to the fund in respect of the period.

Fixed asset investments

Listed investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Consolidated statement of financial activities.

Investments in subsidiaries are valued at cost less provision for impairment.

Other investments consists of fixed term deposit accounts with high street banks and building societies that mature more than one year from the reporting date.

Interest Receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash at bank and in hand

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Group anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Consolidated statement of financial activities as a finance cost.

Current asset investments

Current asset investments are cash or cash equivalents with a maturity date more than three months after the reporting date but less than one year valued at cost.

Going Concern

The Trustees assess whether the use of going concern is appropriate i.e. whether there are any material uncertainties related to events or conditions that may cast significant doubt over the ability of the charity to continue as a going concern. The Trustees make this assessment in respect of a period of at least one year from the date of authorisation for issue of the financial statements and have concluded that the charity has adequate resources to continue in operational existence for the foreseeable future and there are no material uncertainties about the charity's ability to continue as a going concern, thus they continue to adopt the going concern basis of accounting in preparing the financial statements.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

2. CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Group makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Useful economic lives of tangible assets

The annual depreciation charge for tangible fixed assets is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are reassessed annually. They are amended when necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and the physical condition of the assets. See note 16 for the carrying amount of the fixture and fittings and computer equipment and note 1 for the useful economic lives for each class of assets.

Residual legacies

There is some uncertainty in the value of residual legacies recognised due to the time lapse between when probate has been granted and the final distribution is made.

Donated services and facilities

The Group has been donated the use of the premises they operate from. The fair value of the donated facility has been arrived at based on the amount the Group would pay in the open market for an alternative. This has been calculated on an estimated average rate per square foot. While this is considered a reasonable reliable approach there is some uncertainty due to multiple factors affecting the rental value of the property including the size, the age and demographical area.

3. DONATIONS, GRANTS AND LEGACIES

	2025	2024
	£	£
Donations	734,973	683,612
Legacies	196,351	220,913
Grants	440,733	602,877
Donated services and facilities	<u>25,000</u>	<u>25,000</u>
	<u>1,397,057</u>	<u>1,532,402</u>

Donated services and facilities comprise of the use of the premises the Group operates from. The donation represents the deemed market rent of the property.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

3. DONATIONS, GRANTS AND LEGACIES - continued

Grants received included in the above, are as follows:

	2025 £	2024 £
Armed Forces Covenant	-	712
Readleys for provision of benefits advisor	9,733	6,736
UK Government Covid Medical Research	-	133,178
B&CE Charitable Trust for benefits advisor	15,000	-
Memorials Grant Scheme to cover Meso UK's AF Memorial VAT costs	-	4,040
Grants for the provision of nursing services from:		
HASAG	87,344	150,225
LASAG	57,379	22,000
Readleys	22,278	19,952
Mavis Nye foundation	22,000	33,000
Action on Asbestos	58,000	44,000
Asbestos Action	24,000	48,000
SWASAG	11,590	11,498
Meso UK's Legal Panel	39,337	31,124
MAPS Benevolent fund	25,000	25,000
Clydebank Asbestos Group	36,690	-
Meso UK Legal Partner	22,000	-
ASCE	5,382	-
GMAVSG	5,000	-
Grants for research projects from:		
HASAG	-	37,191
Erase-Meso	-	36,221
	440,733	602,877

4. OTHER TRADING ACTIVITIES

	2025 £	2024 £
Trading income	198,806	166,076
Events income	30,516	20,454
One Lottery income	4,242	4,242
Shop income	7,970	12,453
	241,534	203,225

The trading income represents income from Mesothelioma UK commercial relationships which includes:

- Commission from the UK National Asbestos Register
- Income raised from members of Mesothelioma UK Trading Ltd's legal panel, who make payment to Mesothelioma UK Trading Ltd, in return for the inclusion of their name and logo on our website and legal advice leaflet. Their logo is also included on the Mesothelioma Matters magazine, and they each have space for one article in one of the quarterly magazines per year.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

5. INVESTMENT INCOME

	2025	2024
	£	£
Deposit account interest	37,891	21,631
Dividends received	<u>5,691</u>	<u>4,722</u>
	<u>43,582</u>	<u>26,353</u>

6. OTHER INCOME

	2025	2024
	£	£
Rental income	<u>4,260</u>	<u>4,260</u>

7. INCOME FROM CHARITABLE ACTIVITIES

	2025	2024
	£	£
ADDRI income	25,000	-
Speakers fees	250	-
Events income	<u>5,231</u>	<u>5,268</u>
	<u>30,481</u>	<u>5,268</u>

Funds have been provided to Mesothelioma UK to cover the costs incurred supporting the Australian Dust Disease Research Institute (ADDRI) to develop resources, particularly specialist mesothelioma nursing across Australia.

8. RAISING FUNDS

Raising donations and legacies

	2025	2024
	£	£
Staff costs	140,930	124,148
Will writing	3,027	1,817
Stripe and online giving fees	15,051	11,897
Christmas card purchases	1,992	1,869
Fundraising costs	29,155	32,464
Travel expenses	182	193
Charitable events	18,152	17,639
Website and social media	3,301	3,110
Online shop expenses	1,699	3,049
UHL staff costs	36,407	43,111
Head of nursing	<u>2,485</u>	<u>2,225</u>
	<u>252,381</u>	<u>241,522</u>

Other trading expenses

	2025	2024
	£	£
Administration expenses	<u>1,637</u>	<u>1,655</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

9. CHARITABLE ACTIVITIES COSTS

	Direct Costs (see note 10) £	Support costs (see note 11) £	Totals £
Information Expenses	60,815	-	60,815
Awareness Costs	46,535	-	46,535
Research & Audit Costs	160,972	-	160,972
Patient Support Costs	846,997	-	846,997
Administration and operational costs	-	232,247	232,247
	<u>1,115,319</u>	<u>232,247</u>	<u>1,347,566</u>

10. DIRECT COSTS OF CHARITABLE ACTIVITIES

	2025 £	2024 £
Staff costs	192,831	198,529
Provision for nursing services	635,825	649,660
Nurses meetings	2,795	5,200
Website and social media	13,201	12,442
Patient support sundries and other support costs	5,795	5,464
Patient travel	1,135	1,412
Printing and design magazine	4,218	-
Project Wales	140	2,438
Research centre main award	74,312	(1,639)
Other research costs	625	578
Armed Forces project expenses	-	19,611
Information expenses	6,090	11,482
Patient carer day	14,657	11,253
Awareness costs	-	1,671
Travel expenses	-	47
Team leaders	54,034	84,144
Research grants	53,095	108,289
Head of nursing	44,726	40,058
Educational event expenses	2,738	6,006
UHL staff costs	9,102	-
	<u>1,115,319</u>	<u>1,156,645</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

11. SUPPORT COSTS

	Other £	Governance costs £	Totals £
Administration and operational costs	<u>224,145</u>	<u>8,102</u>	<u>232,247</u>

Support costs, included in the above, are as follows:

	2025 £	2024 £
Wages	116,561	140,589
Social security	8,828	10,151
Pensions	8,275	9,613
Rates and water	3,449	4,709
Insurance	1,147	1,032
Telephone	3,943	3,905
Postage and stationery	1,700	1,674
Repairs and maintenance	1,880	751
Legal and professional fees	3,339	6,746
Governance	5,676	4,455
Travel expenses	87	513
Investment manager costs	5,588	6,022
Training	704	106
Subscriptions	1,938	4,888
IT support and other IT costs	12,439	10,597
CRM expenses	8,481	7,349
Marketing and adverts	4,859	2,576
Bank charges	1,265	862
Office expenses	2,077	2,159
Head of nursing	2,485	2,225
Rent	25,000	25,000
Depreciation of tangible fixed assets	4,424	5,120
Auditors' remuneration	<u>8,102</u>	<u>7,630</u>
	<u>232,247</u>	<u>258,672</u>

12. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2025 £	2024 £
Depreciation - owned assets	<u>4,423</u>	<u>5,121</u>

13. AUDITORS' REMUNERATION

	2025 £	2024 £
Fees payable to the charity's auditors for the audit of the charity's financial statements	<u>8,102</u>	<u>7,630</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

14. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2025 nor for the year ended 31 March 2024.

Trustees' expenses

For the year ended 31 March 2025, there was £nil (2024: £191) paid to Mr N Maskell and there was £115 (2024: £50) paid to Ms L Creech.

15. STAFF COSTS

	2025	2024
	£	£
Wages and salaries	403,169	420,504
Social security costs	32,964	33,685
Other pension costs	31,292	28,841
	<u>467,425</u>	<u>483,030</u>

Remuneration of key management personnel

Key management personnel are deemed to be those having authority and responsibility, delegated to them by the trustees for planning, directing and controlling the activities of the charity. The total employee benefits of the key management personnel of the charity amounted to £210,642 (2024: £112,415).

The average monthly number of employees during the year was as follows:

	2025	2024
Support staff	<u>15</u>	<u>16</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2025	2024
£70,001 - £80,000	<u>1</u>	<u>-</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

16. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - 31 MARCH 2024

	Unrestricted fund £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations, grants and legacies	888,469	643,933	1,532,402
Charitable activities - primary trading income	5,268	-	5,268
Other trading activities	203,225	-	203,225
Investment income	26,353	-	26,353
Other income	<u>4,260</u>	<u>-</u>	<u>4,260</u>
Total	<u>1,127,575</u>	<u>643,933</u>	<u>1,771,508</u>
EXPENDITURE ON			
Raising funds	243,177	-	243,177
Charitable activities			
Information Expenses	65,936	-	65,936
Awareness Costs	60,123	19,644	79,767
Research & Audit Costs	59,511	78,197	137,708
Patient Support Costs	360,705	512,529	873,234
Administration and operational costs	<u>258,672</u>	<u>-</u>	<u>258,672</u>
Total	<u>1,048,124</u>	<u>610,370</u>	<u>1,658,494</u>
Net gains on investments	<u>60,065</u>	<u>-</u>	<u>60,065</u>
NET INCOME	139,516	33,563	173,079
RECONCILIATION OF FUNDS			
Total funds brought forward	<u>785,704</u>	<u>324,502</u>	<u>1,110,206</u>
TOTAL FUNDS CARRIED FORWARD	<u>925,220</u>	<u>358,065</u>	<u>1,283,285</u>

**MESOTHELIOMA UK CHARITABLE INCORPORATED
ORGANISATION**

**NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2025**

17. TANGIBLE FIXED ASSETS – GROUP

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 April 2024	3,787	33,554	37,341
Additions	<u>-</u>	<u>2,910</u>	<u>2,910</u>
At 31 March 2025	<u>3,787</u>	<u>36,464</u>	<u>40,251</u>
DEPRECIATION			
At 1 April 2024	2,945	22,087	25,032
Charge for year	<u>126</u>	<u>4,297</u>	<u>4,423</u>
At 31 March 2025	<u>3,071</u>	<u>26,384</u>	<u>29,455</u>
NET BOOK VALUE			
At 31 March 2025	<u>716</u>	<u>10,080</u>	<u>10,796</u>
At 31 March 2024	<u>842</u>	<u>11,467</u>	<u>12,309</u>

TANGIBLE FIXED ASSETS - CHARITY

	Fixtures and fittings £	Computer equipment £	Totals £
COST			
At 1 April 2024	3,787	33,554	37,341
Additions	<u>-</u>	<u>2,910</u>	<u>2,910</u>
At 31 March 2025	<u>3,787</u>	<u>36,464</u>	<u>40,251</u>
DEPRECIATION			
At 1 April 2024	2,945	22,087	25,032
Charge for year	<u>126</u>	<u>4,297</u>	<u>4,423</u>
At 31 March 2025	<u>3,071</u>	<u>26,384</u>	<u>29,455</u>
NET BOOK VALUE			
At 31 March 2025	<u>716</u>	<u>10,080</u>	<u>10,796</u>
At 31 March 2024	<u>842</u>	<u>11,467</u>	<u>12,309</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

18. FIXED ASSET INVESTMENTS – GROUP

	2025 £	2024 £
Shares	544,641	791,075
Other	<u>255,638</u>	<u>-</u>
	<u>800,279</u>	<u>791,075</u>

Additional information as follows:

	Listed investments £	Cash and settlements pending £	Totals £
MARKET VALUE			
At 1 April 2024	774,647	16,428	791,075
Additions	91,771	343,069	434,840
Disposals	(337,378)	(347,359)	(684,737)
Revaluations	<u>3,463</u>	<u>-</u>	<u>3,463</u>
At 31 March 2025	<u>532,503</u>	<u>12,138</u>	<u>544,641</u>
NET BOOK VALUE			
At 31 March 2025	<u>532,503</u>	<u>12,138</u>	<u>544,641</u>
At 31 March 2024	<u>774,647</u>	<u>16,428</u>	<u>791,075</u>

FIXED ASSET INVESTMENTS – CHARITY

	2025 £	2024 £
Shares	544,642	791,076
Other	<u>255,638</u>	<u>-</u>
	<u>800,280</u>	<u>791,076</u>

Additional information as follows:

	Shares in group undertakings £	Listed investments £	Cash and settlements pending £	Totals £
MARKET VALUE				
At 1 April 2024	1	774,647	16,428	791,076
Additions	-	91,771	343,069	434,840
Disposals	-	(337,378)	(347,359)	(684,737)
Revaluations	<u>-</u>	<u>3,463</u>	<u>-</u>	<u>3,463</u>
At 31 March 2025	<u>1</u>	<u>532,503</u>	<u>12,138</u>	<u>544,642</u>
NET BOOK VALUE				
At 31 March 2025	<u>1</u>	<u>532,503</u>	<u>12,138</u>	<u>544,642</u>
At 31 March 2024	<u>1</u>	<u>774,647</u>	<u>16,428</u>	<u>791,076</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

FIXED ASSET INVESTMENTS – CHARITY - continued

Cost or valuation at 31 March 2025 is represented by:

	Shares in group undertakings £	Listed investments £	Cash and settlements pending £	Totals £
Valuation in 2025	-	532,503	-	532,503
Cost	<u>1</u>	<u>-</u>	<u>12,138</u>	<u>12,139</u>
	<u><u>1</u></u>	<u><u>532,503</u></u>	<u><u>12,138</u></u>	<u><u>544,642</u></u>

The charity's investments at the balance sheet date in the share capital of companies include the following:

Mesothelioma UK Trading Limited

Registered office: 235 Loughborough Road, Mountsorrel, Loughborough, LE12 7AS

Company number: 12541690

Nature of business: Sponsorship and advertising sales

Class of share: %
holding
Ordinary 100

	2025 £	2024 £
Aggregate capital and reserves	1	1
Profit for the year	<u>197,169</u>	<u>164,421</u>

FIXED ASSET INVESTMENTS – GROUP AND CHARITY

Investments (neither listed nor unlisted) were as follows:

	2025 £	2024 £
Bank deposits	<u>255,638</u>	<u>-</u>

Other investments consists of fixed term deposit accounts with high street banks and building societies which mature in more than a year.

There were no investment assets outside the UK.

19. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR - GROUP

	2025 £	2024 £
Trade debtors	28,431	14,599
Other debtors	10,449	5,817
Prepayments and accrued income	<u>129,644</u>	<u>208,733</u>
	<u><u>168,524</u></u>	<u><u>229,149</u></u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

19. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR - CHARITY

	2025	2024
	£	£
Trade debtors	10,168	13,798
Amounts owed by group undertakings	3,982	-
Other debtors	10,449	5,817
Prepayments and accrued income	129,644	208,733
	<u>154,243</u>	<u>228,348</u>

20. CURRENT ASSET INVESTMENTS – GROUP AND CHARITY

	2025	2024
	£	£
Bank deposits	-	100,738

Current asset investments consists of fixed rate deposits with high street banks and building societies that mature more than 3 months after the reporting date but less than 12 months.

21. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR - GROUP

	2025	2024
	£	£
Trade creditors	84,241	65,983
Social security and other taxes	17,758	14,376
Other creditors	4,676	4,954
Accruals and deferred income	73,922	123,703
	<u>180,597</u>	<u>209,016</u>

CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR - CHARITY

	2025	2024
	£	£
Trade creditors	84,241	65,983
Amounts owed to group undertakings	-	10,105
Social security and other taxes	9,318	9,311
Other creditors	4,676	4,954
Accruals and deferred income	68,082	117,863
	<u>166,317</u>	<u>208,216</u>

Within accruals and deferred income are funds received in advance from fundraising challenges yet to take place at the year end. The deferred income is £16,163 (2024: £11,097). The events are expected to take place in 2025/26.

22. LEASING AGREEMENTS – GROUP AND CHARITY

Minimum lease payments under non-cancellable operating leases fall due as follows:

	2025	2024
	£	£
Within one year	25,000	25,000
Between one and five years	100,000	100,000
In more than five years	37,093	62,093
	<u>162,093</u>	<u>187,093</u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

23. MOVEMENT IN FUNDS

	At 1.4.24 £	Net movement in funds £	At 31.3.25 £
Unrestricted funds			
General fund	925,220	125,075	1,050,295
Restricted funds			
Grants and donations for nurses	31,881	16,277	48,158
Project NI	39,074	-	39,074
Grants and donations for research	149,183	(94,119)	55,064
Grants and donations for other restricted projects	8,653	12,624	21,277
Project Wales	19,801	(8,246)	11,555
Mick May Memorial Fund	109,473	52,599	162,072
Commonwealth Mesothelioma Research Network	-	14,583	14,583
	<u>358,065</u>	<u>(6,282)</u>	<u>351,783</u>
TOTAL FUNDS	<u><u>1,283,285</u></u>	<u><u>118,793</u></u>	<u><u>1,402,078</u></u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	1,172,825	(1,051,213)	3,463	125,075
Restricted funds				
Grants and donations for nurses	418,834	(402,557)	-	16,277
Grants and donations for research	7,041	(101,160)	-	(94,119)
Grants and donations for other restricted projects	37,968	(25,344)	-	12,624
Project Wales	1,010	(9,256)	-	(8,246)
Mick May Memorial Fund	52,599	-	-	52,599
Commonwealth Mesothelioma Research Network	25,000	(10,417)	-	14,583
	<u>542,452</u>	<u>(548,734)</u>	<u>-</u>	<u>(6,282)</u>
TOTAL FUNDS	<u><u>1,715,277</u></u>	<u><u>(1,599,947)</u></u>	<u><u>3,463</u></u>	<u><u>118,793</u></u>

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

23. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.4.23 £	Net movement in funds £	At 31.3.24 £
Unrestricted funds			
General fund	785,704	139,516	925,220
Restricted funds			
Grants and donations for nurses	141,276	(109,395)	31,881
Armed Forces Grant	1,474	(1,474)	-
Project NI	35,714	3,360	39,074
Grants and donations for research	-	149,183	149,183
Grants and donations for other restricted projects	24,826	(16,173)	8,653
Project Wales	11,739	8,062	19,801
Mick May Memorial Fund	109,473	-	109,473
	<u>324,502</u>	<u>33,563</u>	<u>358,065</u>
TOTAL FUNDS	<u>1,110,206</u>	<u>173,079</u>	<u>1,283,285</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Gains and losses £	Movement in funds £
Unrestricted funds				
General fund	1,125,921	(1,046,470)	60,065	139,516
Restricted funds				
Grants and donations for nurses	385,747	(495,142)	-	(109,395)
Armed Forces Grant	712	(2,186)	-	(1,474)
Project NI	3,360	-	-	3,360
Grants and donations for research	206,590	(57,407)	-	149,183
Grants and donations for other restricted projects	17,023	(33,196)	-	(16,173)
Project Wales	10,500	(2,438)	-	8,062
Cost-Benefit study	20,000	(20,000)	-	-
	<u>643,932</u>	<u>(610,369)</u>	<u>-</u>	<u>33,563</u>
TOTAL FUNDS	<u>1,769,853</u>	<u>(1,656,839)</u>	<u>60,065</u>	<u>173,079</u>

Unrestricted funds are available to be spent for any purposes of the charity.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

23. MOVEMENT IN FUNDS - continued

Purposes of restricted funds

Grants and donations for nurses

Various grants and donations were received during the year towards the cost of the Mesothelioma UK clinical nurse specialists and team leaders.

Project NI

These are ring-fenced donations restricted for Mesothelioma UK to establish or expand services across Northern Ireland. Mesothelioma UK clinical nurse specialists have been recruited for Northern Ireland who will lead the development of appropriate services.

Project Wales

These are ring-fenced donations restricted for Mesothelioma UK to establish or expand services across Wales. Mesothelioma UK clinical nurse specialists have been recruited in the region who will lead the development of appropriate services.

Mick May Memorial Fund

Most of the funds in the MMMF were a grant from the Schroder Foundation. This is for use under the 'Improving Outcomes and Experience' pillar, to ensure patients have equitable access to the best treatment, care, information and support including helping to build a comprehensive multi-disciplinary team approach and evidenced based care pathways and guidelines which are fundamental to achieving improved outcomes and experiences.

Commonwealth Mesothelioma Research Network

Mesothelioma UK are supporting the Australian Dust Disease Research Institute (ADDRI) to develop resources, particularly specialist mesothelioma nursing, across Australia. In addition the two organisations have established an international research network and together they plan to develop a menu of resources and events to help share mesothelioma specific learning, expertise and knowledge across all countries in the commonwealth.

Grants for Research

Donations were received restricted for both general research and specific research projects.

Grants for other restricted projects

Other donations were received and restricted for the education of the nurses, towards the funding of Mesothelioma UK benefits advisors, towards the funding of support groups and to help towards travel costs.

24. EMPLOYEE BENEFIT OBLIGATIONS

The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Group in an independently administered fund. The pension cost charges represent the contributions payable by the charity to the fund in the year and amount to £31,292 (2024: £28,841). At the balance sheet date £4,640 (2024: £3,620) were payable to the fund and are included in creditors.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 31 MARCH 2025

24. CONTINGENT ASSET

The Group has been notified of an entitlement to legacies of which the Group is unable to measure reliably the value of amounts due and therefore no provision has been made in the accounts.

25. RELATED PARTY DISCLOSURES

A L Coates is a Trustee of the parent charity and a partner of Irwin Mitchell Solicitors. During the period, £64,059 (2024: £36,828) was receivable by the group from Irwin Mitchell Solicitors being £27,600 (2024: £24,000) sponsorship income plus £36,459 (2024: £12,828) from fundraising events and donations. Also, during the period, the group acquired will writing and other professional services from Irwin Mitchell Solicitors at a cost of £2,204 (2024: £1,547).

D McKinley was a Trustee of the parent charity, resigning on 31 December 2024, and Senior Executive Officer of the British Thoracic Oncology Group (BTOG). During the period, BTOG paid rent to the parent charity of £4,260 (2024: £4,260) and received amounts for recharged expenses of £360 (2024: £194).

C Evans is a Trustee of the parent charity and Chief Operating Officer at UK Asbestos Training Association Ltd (UKATA). During the period, UKATA made a donation of £30 (2024: £nil) to the parent charity.

A Jones is a Trustee of the parent charity and a partner of Thompsons Solicitors LLP. During the period, £39,909 (2024: £nil) was receivable by the group from Thompsons Solicitors LLP being £27,600 (2024: £nil) sponsorship income plus £12,309 (2024: £nil) from fundraising events and donations.

L Darlison is the Chief Executive Officer of the parent charity and Director of the trading company. During the period, No More Mist provided repairs to the group of £52 (2024: £nil), this entity is owned by Liz's spouse, S Darlison. In addition, L&E Electrical Contractors provided maintenance work of £163 (2024: £nil), in which Liz's son in law, S Lewitt, is a shareholder and director.

H Childs resigned as a Trustee of the parent charity on 27 March 2024 and is a partner of Royds Withy King Solicitors. During 2024, £28,134 was receivable by the group from Royds Withy King Solicitors being £28,134 worth of sponsorship income. As H Childs resigned in the previous accounting period there are no further related party transactions to disclose.

26. CONTRIBUTIONS OF VOLUNTEERS AND SUPPORTERS

The charity is grateful for the unstinting efforts of volunteer fundraisers who take part in a wide range of sponsored events and other fundraising activities. The vast majority of income comes from private individuals making donations, participating in sponsored events, or leaving legacies.

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

DETAILED CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

	2025 £	2024 £
INCOME AND ENDOWMENTS		
Donations, grants and legacies		
Donations	734,973	683,612
Legacies	196,351	220,913
Grants	440,733	602,877
Donated services and facilities	<u>25,000</u>	<u>25,000</u>
	1,397,057	1,532,402
Income from charitable activities		
ADDRI income	25,000	-
Speaker fees	250	-
Events income	<u>5,231</u>	<u>5,268</u>
	30,481	5,268
Other trading activities		
Trading income	198,806	166,076
Events income	30,516	20,454
One Lottery income	4,242	4,242
Shop income	<u>7,970</u>	<u>12,453</u>
	241,534	203,225
Investment income		
Deposit account interest	37,891	21,631
Dividends received	<u>5,691</u>	<u>4,722</u>
	43,582	26,353
Other income		
Rental income	<u>4,260</u>	<u>4,260</u>
Total incoming resources	1,716,914	1,771,508
EXPENDITURE		
Raising donations and legacies		
Wages	120,980	108,463
Social security	9,958	8,294
Pensions	9,992	7,391
Will writing	3,027	1,817
Stripe and online giving fees	15,051	11,897
Christmas card purchases	1,992	1,869
Fundraising costs	29,155	32,464
Travel expenses	182	193
Charitable events	18,152	17,639
Website and social media	3,301	3,110
Online shop expenses	1,699	3,049
UHL staff costs	36,407	43,111
Head of nursing	<u>2,485</u>	<u>2,225</u>
	252,381	241,522

This page does not form part of the statutory financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

DETAILED CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

	2025 £	2024 £
Other trading expenses		
Administration expenses	1,637	1,655
Charitable activities		
Wages	165,628	171,452
Social security	14,178	15,240
Pensions	13,025	11,837
Provision for nursing services	635,825	649,660
Nurses meetings	2,795	5,200
Website and social media	13,201	12,442
Patient support sundries and other support costs	5,795	5,464
Patient travel	1,135	1,412
Printing and design magazine	4,218	-
Project Wales	140	2,438
Research centre main award	74,312	(1,639)
Other research costs	625	578
Armed Forces project expenses	-	19,611
Information expenses	6,090	11,482
Patient carer day	14,657	11,253
Awareness costs	-	1,671
Travel expenses	-	47
Team leaders	54,034	84,144
Research grants	53,095	108,289
Head of nursing	44,726	40,058
Educational event expenses	2,738	6,006
UHL staff costs	9,102	-
	1,115,319	1,156,645
Support costs		
Other		
Wages	116,561	140,589
Social security	8,828	10,151
Pensions	8,275	9,613
Rates and water	3,449	4,709
Insurance	1,147	1,032
Telephone	3,943	3,905
Postage and stationery	1,700	1,674
Repairs and maintenance	1,880	751
Legal and professional fees	3,339	6,746
Governance	5,676	4,455
Travel expenses	87	513
Investment manager costs	5,588	6,022
Training	704	106
Subscriptions	1,938	4,888
IT support and other IT costs	12,439	10,597
CRM expenses	8,481	7,349
Carried forward	184,035	213,100

This page does not form part of the statutory financial statements

MESOTHELIOMA UK CHARITABLE INCORPORATED ORGANISATION

DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

	2025 £	2024 £
Other		
Brought forward	184,035	213,100
Marketing and adverts	4,859	2,576
Bank charges	1,265	862
Office expenses	2,077	2,159
Head of nursing	2,485	2,224
Rent	25,000	25,000
Depreciation of tangible fixed assets	4,424	5,121
	224,145	251,042
Governance costs		
Auditors' remuneration	8,102	7,630
Total resources expended	1,601,584	1,658,494
Net income before gains and losses	115,330	113,014
Realised recognised gains and losses		
Realised gains/(losses) on fixed asset investments	3,463	60,065
Net income	118,793	173,079

This page does not form part of the statutory financial statements